WO1998008818A1 - Inhibitors of phospholipase enzymes - Google Patents

Inhibitors of phospholipase enzymes Download PDF

Info

Publication number
WO1998008818A1
WO1998008818A1 PCT/US1997/014943 US9714943W WO9808818A1 WO 1998008818 A1 WO1998008818 A1 WO 1998008818A1 US 9714943 W US9714943 W US 9714943W WO 9808818 A1 WO9808818 A1 WO 9808818A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
mmol
compound
independent
prepared
Prior art date
Application number
PCT/US1997/014943
Other languages
French (fr)
Inventor
Yibin Xiang
Jean Bemis
John Mckew
Neelu Kaila
Original Assignee
Genetics Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc. filed Critical Genetics Institute, Inc.
Priority to JP10511798A priority Critical patent/JP2000516958A/en
Priority to EP97938589A priority patent/EP0922028A1/en
Priority to AU40882/97A priority patent/AU717430B2/en
Priority to CA002264020A priority patent/CA2264020A1/en
Publication of WO1998008818A1 publication Critical patent/WO1998008818A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to chemical inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A, enzymes.
  • Leukotrienes and prostaglandins are important mediators of inflammation. Leukotrienes recruit inflammatory cells such as neutrophils to an inflamed site, promote the extravasation of these cells and stimulate release of superoxide and proteases which damage the tissue. Leukotrienes also play a pathophysiological role in the hypersensitivity experienced by asthmatics [See, e.g. B. Samuelson et al., Science. 227: 1 171-76 ( 1987)].
  • Prostaglandins enhance inflammation by increasing blood flow and therefore infiltration of leukocytes to inflamed sites. Prostaglandins also potentiate the pain response induced by stimuli. Prostaglandins and leukotrienes are unstable and are not stored in cells, but are instead synthesized [W. L. Smith, Biochem. J.. 259:315-324 (1989)] from arachidonic acid in response to stimuli. Likewise arachidonic acid is not free in cells but is released from the sn-2 position of membrane phospholipids by phospholipase A : (hereinafter PLA 2 ). The reaction catalyzed by PLA 2 is believed to represent the rate-limiting step in the process of lipid mediated biosynthesis.
  • the lysophospholipid produced is the immediate precursor of platelet activating factor (hereafter called PAF), another potent mediator of inflammation [S.I. Wasserman, Hospital Practice, 15:49-58 ( 1988)]. Consequently the direct inhibition of the activity of PLA ; has been suggested as a useful mechanism for a therapeutic agent, i.e.. to interfere with the inflammatory response. [See, e.g., J. Chang et al, Biochem. Pharmacol.. 36:2429-2436 (1987)].
  • PAF platelet activating factor
  • PLA- enzymes characterized by the presence of a secretion signal sequenced and ultimately secreted from the cell have been sequenced and structurally defined. These secreted PLA,s have an approximately 14 kD molecular weight and contain seven disulfide bonds which are necessary for activity. These PLA,s are found in large quantities in mammalian pancreas, bee venom, and various snake venom. [See, e.g., references 13-15 in Chang et al, cited above; and E. A. Dennis, Drug Devel. Res.. 10:205-
  • pancreatic enzyme is believed to serve a digestive function and, as such, should not be important in the production of the inflammatory mediators whose production must be tightly regulated.
  • the primary structure of the first human non-pancreatic PLA has been determined.
  • This non-pancreatic PLA is found in platelets, synovial fluid, and spleen and is also a secreted enzyme
  • This enzyme is a member of the aforementioned family [See, J J Seilhamer et al. J Biol Chem . 264 5335-5338 (1989). R M Kramer et al. J Biol Chem . 264 5768-5775 (1989), and A Kando et al, Biochem Biophvs Res Comm .
  • a mu ⁇ ne PLA- has been identified in the mu ⁇ ne macrophage cell line, designated RAW 264 7
  • RAW 264 7 A specific activity of 2 ⁇ mols/min/mg, resistant to reducing conditions, was reported to be associated with the approximately 60 kD molecule
  • this protein was not pu ⁇ fied to homogeneity [See, C C Leslie et al, Biochem Biophvs Acta .
  • the present invention provides compounds having a chemical formula selected from the group consisting of:
  • A is independent of any other group and is selected from the group consisting of -CH 2 - and -CH 2 -CH 2 -;
  • R is independent of any other R group and is selected from the group consisting of -X-R 6 , -H. -OH, halogen, -CN, -N0 2 , C,-C, alkyl, alkenyl, alkinyl, aryl and substituted aryl;
  • R 2 is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR,, -CONR,R 6 , -(CH 2 ) n -W-(CH 2 ) m -Z-R réelle -(CH 2 ) deliberately-W-R discipline -Z-Rpractic C,-C, 0 alkyl, alkenyl and substituted aryl;
  • R is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR 5 , -CONR,R 6 , -(CH 2 ) n -W-(CH 2 ) m -Z-R s , (CH 2 ) n -W-Rlois -Z-R profession C r C l0 alkyl, alkenyl and substituted aryl;
  • R 4 is independent of any other R group and is selected from the group consisting of -H, -OH, -OR 6 , -SR 6 , -CN, -COR 6 , -NHR 6 , -COOH, -CONR 6 R 7 , -N0 2 , -CONHS0 2 R R , C,- C 5 alkyl, alkenyl and substituted aryl;
  • R is independent of any other R group and is selected from the group consisting of -H, -OH, -0(CH 2 ) n R 6 , -SR 6 , -CN, -COR 6 , -NHR 6 , -COOH, -N0 2 , -COOH, -CONR ⁇ R 7 , -CONHSO : R 8 , C r C, alkyl, alkenyl, alkinyl, aryl, substituted aryl, -CF essence -CF,CF, and
  • R 6 is independent of any other R group and is selected from the group consisting of -H, C,-C 3 alkyl, alkenyl, alkinyl, aryl and substituted aryl,
  • R 7 is independent of any other R group and is selected from the group consisting of -H, C,-C, alkyl, alkenyl, alkinyl, aryl and substituted aryl,
  • R 8 is independent of any other R group and is selected from the group consisting of C,-C 3 alkyl, aryl and substituted aryl,
  • R is independent of any other R group and is selected from the group consisting of -H, -OH, a halogen, -CN, -OR 6 , -COOH, -CONR 6 R 7 , tetrazole, -CONHS0 2 R 8 , -COR ⁇ , -(CH 2 ) n CH(OH)R 6 and -(CH 2 ) n CHR 6 R flesh
  • R ⁇ 0 is independent of any other R group and is selected from the group consisting of -H, -OH, a halogen, -CN, -OR 6 , -COOH, -CONR 6 R 7 , tetrazole, -CONHS0 2 R 8 , -COR 6 , -(CH 2 ) felicitCH(OH)R 6 and -(CH 2 ) n CHR 6 R 5 ,
  • X is independent of any other group and is, independently each time used including within the same compound, selected from the group consisting of -O-, -S- and -N(R6)-,
  • Z is independent of any other group and is, independently each time used including within the same compound, selected from the group consisting of -CH 2 -, -0-, -S-, -N(R 6 )-, - CO-, -CON(R 6 )- and -N(R lake)CO-, m is, independently each time used including within the same compound, an integer from 0 to 4, and n is independent of m and is, independently each time used including within the same compound, an integer from 0 to 4
  • the compounds of the invention have phospholipase enzyme inhibiting activity
  • Other preferrred embodiments include compounds having the following chemical formula
  • A is -CH 2 - and R 2 is
  • R ⁇ is selected froup the group consisting of alkyl, alkenyl, alkynyl, -(CH 2 ) p OH, and -0(CH 2 ) p CH 3 , and wherein p is an integer from 0 to 4.
  • R is selected from the group consisting of -H and -OCH 2 (C 6 H 6 ) and R, is -COR , R 5 is -OCH 2 R 6 and R 6 is a substituted aryl group.
  • said aryl group is substituted with one or more substituents selected from the group consisting of -CF 3 , -CF 2 CF 3 and -C(CH,) 2 CH 2 CH 3 .
  • the present invention also provides for a method of inhibiting the phospholipase enzyme activity of an enzyme, comprising administering to a mammalian subject a therapeutically effective amount of a compound of the present invention.
  • Methods of treating an inflammatory condition comprising administering to a mammalian subject a therapeutically effective amount of a compound of the present invention are also provided.
  • Pharmaceutical compositions comprising compounds of the present invention and a pharmaceutically acceptable carrier are also provided.
  • Pharmaceutically acceptable salts of the compounds of the compounds desc ⁇ bed herein are also part of the present invention and may be used in practicing the compounds and methods disclosed herein.
  • Figs. 1 -13 depict schemes for synthesis of compounds of the present invention. The depicted schemes are desc ⁇ bed in further detail below.
  • halogen includes chlo ⁇ ne, fluorine, iodine and bromine; "alkyl”,
  • alkenyl and alkinyl include both straight chain and branched moieties; “aryl” includes single and multiple ⁇ ng moieties; and “substituted” denotes the presence of one or more similar ot dissimilar substituent groups of any character.
  • Tables I-VI also report data for the listed compounds in the "LysoPC” assay and the Coumarine assay (see Example 88 below).
  • assay results are reported as an "IC 50 " value, which is the concentration of a compound which inhibits 50% of the activity of the phospholipase enzyme in such assay. Where no nume ⁇ cal IC 50 value appears, "NA” denotes that inhibitory activity was not detected from such compound in the corresponding assay and a blank box denotes that the compound was not tested in such assay as of the time of filing of the present application
  • phospholipase enzyme activity means positive activity in an assay for metabolism of phospholipids (preferably one of the assays desc ⁇ bed in Example 88 below).
  • a compound has "phospholipase enzyme inhibiting activity” when it inhibits the activity of a phospholipase (preferably cPLA 2 ) in any available assay (preferably an assay desc ⁇ bed below in Example 88 or Example 89) for enzyme activity
  • a compound has ( 1 ) an IC S0 value of less than about 25 ⁇ M, preferably less than about 6 ⁇ M, in the LysoPC assay, (2) an IC S0 value of less than about 50 ⁇ M in the vesicle assay; (3) an IC ⁇ ;o value of less than about 1 ⁇ M in the PMN assay, (4) an IC 50 value of less than about 15 ⁇ M in the Couma ⁇ ne assay, and/or (5) measurable activity (preferably at least about 5% reduction in edema, more
  • Compounds of the present invention are useful for inhibiting phospholipase enzyme (preferably cPLA,) activity and, therefore, are useful in "treating” (I e., treating, preventing or ameliorating) inflammatory or inflammation-related conditions (e.g., rheumatoid arth ⁇ tis, pso ⁇ asis, asthma, inflammatory bowel disease, and other diseases mediated by prostaglandins, leukot ⁇ enes or PAF) and other conditions, such as osteoporosis, colitis, myelogenous leukemia, diabetes, wasting and atherosclerosis
  • the present invention encompasses both pharmaceutical compositions and therapeutic methods of treatment or use which employ compounds of the present invention
  • compositions when combined with a pharmaceutically acceptable earner
  • a pharmaceutically acceptable earner Such a composition may also contain (in addition to a compound or compounds of the present invention and a earner) diluents, fillers, salts, buffers, stabilizers, solubihzers, and other mate ⁇ als well known in the art
  • pharmaceutically acceptable means a non-toxic mate ⁇ al that does not interfere with the effectiveness of the biological activity of the active ⁇ ngred ⁇ ent(s) The characte ⁇ stics of the earner will depend on the route of administration.
  • the pharmaceutical composition may further contain other anti-inflammatory agents Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with compounds of the present invention, or to minimize side effects caused by the compound of the present invention
  • the pharmaceutical composition of the invention may be in the form of a liposome in which compounds of the present invention are combined, in addition to other pharmaceutically acceptable earners, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution
  • Suitable lipids for hposomal formulation include, without limitation, monoglyce ⁇ des, diglyce ⁇ des, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like
  • Preparation of such hposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S Patent No 4,235,871 , U.S Patent No 4,501 ,728, U S Patent No 4,837,028, and U S Patent No 4,737,323, all of which are incorporated herein by reference
  • the term "therapeutically effective amount” means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, l e , treatment, healing, prevention or amelioration of an inflammatory response or condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions
  • the term refers to that ingredient alone
  • the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, se ⁇ ally or simultaneously
  • a therapeutically effective amount of a compound of the present invention is administered to a mammal having a condition to be treated
  • Compounds of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing other anti-inflammatory agents, cytokines, lymphokines or other hematopoietic factors
  • compounds of the present invention may be administered either simultaneously with the other anti-inflammatory agent(s), cytok ⁇ ne(s), lymphok ⁇ ne(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially If administered sequentially, the attending physician will decide on the approp ⁇ ate sequence of ad iniste ⁇ ng compounds of the present invention in combination with other anti- lnflammatory agent(s), cytokme(s), lymphok
  • compounds of the present invention When a therapeutically effective amount of compounds of the present invention is administered orally, compounds of the present invention will be in the form of a tablet, capsule, powder, solution or elixir
  • the pharmaceutical composition of the invention may additionally contain a solid earner such as a gelatin or an adjuvant
  • a solid earner such as a gelatin or an adjuvant
  • the tablet, capsule, and powder contain from about 5 to 95% compound of the present invention, and preferably from about 25 to 90% compound of the present invention
  • a liquid earner such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil. soybean oil, or sesame oil, or synthetic oils may be added.
  • the liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene giycol.
  • the pharmaceutical composition When administered in liquid form, contains from about 0.5 to 90% by weight of compound of the present invention, and preferably from about 1 to 50% compound of the present invention.
  • compounds of the present invention When a therapeutically effective amount of compounds of the present invention is administered by intravenous, cutaneous or subcutaneous injection, compounds of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution.
  • parenterally acceptable protein solutions having due regard to pH, isotonicity, stability, and the like, is within the skill in the art.
  • a preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to compounds of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium
  • the pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
  • the amount of compound(s) of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of compound of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of compound of the present invention and observe the patient's response.
  • the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.1 ⁇ g to about 100 mg of compound of the present invention per kg body weight.
  • the duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the compounds of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
  • Indol-2-carboxylic acid ethyl ester I is converted to aldehyde II in two steps: reduction with lithium aluminum hydride (LAH) or other hydride in a suitable solvent such as tetrahydrofuran (THF) at 0 °C, and then oxidation with an oxidizing reagent such as manganese dioxide in a solvent such as THF.
  • LAH lithium aluminum hydride
  • THF tetrahydrofuran
  • an oxidizing reagent such as manganese dioxide in a solvent such as THF.
  • Deprotonation of aldehyde II with a strong base such as potassium hexamethyldisilyl amide (KHMDS) in THF followed by reaction with a chloroformate in the presence of a base, such as triethyl amine, produces carbamate III.
  • KHMDS potassium hexamethyldisilyl amide
  • Ill is transformed into bromide IV in two steps: (1 ) reduction with sodium borohydride in an alcoholic solution and (2) reaction withcarbon tetrabromide in the presence of a phosphine reagent such as bis(diphenylphosphino)propane in dichloromethane.
  • a phosphine reagent such as bis(diphenylphosphino)propane in dichloromethane.
  • Displacement of the bromine in IV with potassium phenoxide, prepared by reaction of a phenol with KHMDS, in a suitable solvent such as THF or DMF affords ether V.
  • V can be converted to either trifluoromethyl ketone VII or to carboxylic acid IX in different procedures.
  • 2-Indolyl carboxylic acid ethyl ester I is deprotonated with a strong base such as sodium hydride (NaH) in THF, and then reacted with a suitable alkyl bromide to give X.
  • a strong base such as sodium hydride (NaH) in THF
  • a suitable alkyl bromide to give X.
  • Hydrolysis of X with a aqueous base such as sodium hydroxide and reaction with aniline or a substituted aniline in the presence of a carbodiimide such as dimethylaminopropyl ethylcarbodiimide hydrochlo ⁇ de (EDCI) in a suitable solvent such as dichloromethane affords amide XI XI is hydrolyzed to corresponding acid XII in a aqueous base such as sodium hydroxide
  • Indole I can be brominated on the 3-pos ⁇ t ⁇ on by reaction with a bromine or N- bromosucci ⁇ imide in a suitable solvent such ascarbon tetrachlo ⁇ de or dichloromethane to yield bromide XIII
  • a suitable alkyl bromide in the presence of a strong base such as NaH in THF or DMF affords indole XIV
  • Palladium mediated coupling of XIV with a suitable alkene in the presence of phosphine and a base such as t ⁇ ethyl amine produces 3-subst ⁇ tuted indole XV
  • XV can be converted to amide XVII in two step reactions ( 1 ) hydrolysis with aqueous base such as NaOH and (2) coupling with an amine in the presence of carbodiimide such as EDCI Ester XIV can be transformed to lithium salt XVIII by hydrolysis with aqueous base and then reaction with lithium hydroxide in a
  • Indole I can be converted to XXI in two steps ( 1 ) reduction with LAH in a solvent such as
  • Aldehyde II prepared by Method A, can be alkylated by a suitable alkyl bromide (or iodide), such as benzyl bromide or ethyl iodide in the presence of a strong base such as sodium hydnde or KHMDS in a solvent such as DMF to yield XXV
  • XXV can be converted to an unsaturated acid XXVI by two steps (1 ) Wittig reaction with a suitable reagent such as t ⁇ methyl phosphonoacetate in the presence of a base such as sodium hydnde in a solvent such as THF and (2) Hydrolysis by aqueous sodium hydroxide Coupling reaction of XXVI with an amine catalyzed by a dnmide such as EDCI (dimethylaminopropyl ethylcarbodnmide hydrochlo ⁇ de), followed by hydrolysis with aqueous base such as sodium hydroxide affords XX
  • Indole I is reduced with LAH in a solvent such as THF A second reduction with sodium cyanoborohyd ⁇ de in a solvent such as acetic acid to yield alcohol XXVIII Protection of the nitrogen of XXVIII with t-butoxycarbonyl (BOC) using di-t-butyldicarbonate ((BOC) 3 0) in the presence of a base such as tnethylamine affords carbamate XXIX The hydroxyl group in XXIX is mesylated using mesyl chlo ⁇ de and tnethylamine in a solvent such as dichloromethane, and then displaced by either a thiol or an alcohol as desc ⁇ bed in
  • XXXI is either acylated (acyl chlo ⁇ de, tnethylamine, dichloromethane) or alkylated (alkyl ha de, K 2 CO DMF) to afford XXXII, or XXXIII respectively
  • Carboxylic acid XXXIV is converted to aldehyde XXXV in two steps ( 1) reaction with N.O-dimethylhydroxy amine in the presence of EDCI in a solvent such as dichloromethane, and (2) reduction with diisobutyl aluminum hydride (DIBAL) in a solvent such as THF.
  • DIBAL diisobutyl aluminum hydride
  • Treatment of XXXV with trimethyl phosphonoacetate in the presence of a strong base such as KHMDS in a solvent such as THF results in the formation of ester XXXVI.
  • Reduction of XXXVI with tin in hydrogen chloride, followed by cyclization in a heated inert solvent such as toluene gives XXXVII.
  • Aldehyde XXXV prepared in METHOD G, is subjected to a Wittig reaction using methyl triphenylphosphonium iodide in the presence of a strong base such as KHMDS or NaH in a solvent such as THF to afford alkene XL.
  • a strong base such as KHMDS or NaH in a solvent such as THF
  • Reduction of the nitro group of XL with iron powder in an ammonium chloride solution, followed by treatment with benzyl chloroformate in the presence of a base such as triethyl amine produces carbamate XLI.
  • XLI is treated with iodine in a basic solution such as aqueous NaHCO, in THF to yield iodide XLII.
  • Displacement of the iodine on XLII with lithium benzoate in a solvent such as DMF, followed by hydrolysis with NaOH affords alcohol XLIII.
  • Indoline XXVIII prepared in METHOD F or METHOD H. can be either acylated by reaction with an acyl chloride in the presence of a base such as triethyl amine or alkylated using alkyl halide in the presence of K- j CO, in a solvent such as DMF to produce alcohol XLIV.
  • a base such as triethyl amine or alkylated using alkyl halide in the presence of K- j CO
  • a solvent such as DMF
  • METHOD J illustrates the synthesis of alpha-substituted aminophenylacetic acid esters
  • Ester L can be deprotonated with a strong base such as lithium dnsobutylamide (LDA) in a solvent such as THF, and subsequently alkylated with an alkyl halide such as methyl iodide to give LI
  • Reduction of LI to amine LIII can be accomplished using hydrogenation catalyzed by palladium in a solvent such as ethanol L can be oxidized to alcohol LII using LDA and oxazindine in a solvent such as THF
  • Alkylation of LII with a alkylating reagent such as methyl iodide in the presence of a strong base such as NaH in DMF, followed by catalytic hydrogenation in the presence of palladium produces amine LIV
  • METHOD K illustrates the synthesis of substituted aminobenzoic acid esters
  • Mono-acid LV can be converted to amide LVI by the following steps' (1) reaction with oxalyl chlo ⁇ de in dichloromethane to form acid chlo ⁇ de and (2) treatment with a suitable amine such as dimethyl amine
  • Reduction of the nitro group to the amine is accomplished with hydrogenation catalyzed by palladium as desc ⁇ bed in METHOD J LV can be reduced to alcohol LVIII with hydroborane-THF complex in THF Protection of the hydroxy group as a silyl ether using TBDMSCI in the presence of lmidazole and subsequently, reduction of the nitro group (H 2 / Pd-C) to the amine affords LIX LVIII can be converted to the secondary alcohol LX in two steps.
  • Alcohol LXrV prepared in METHOD I, can be debenzylated by hydrogenolysis catalyzed by palladium on carbon in a solvent such as ethanol
  • a solvent such as ethanol
  • the resulting alcohol is treated with p-methoxybenzyl chlo ⁇ de in the presence of K 2 C0 3 in a solvent such as THF to afford
  • LXV Alcohol LXV can be transformed into ether or sulfide LXVI by the procedures desc ⁇ bed in METHOD D Deprotection of the p-methoxybenzyl group with TFA in a solvent such as dichloromethane, and subsequent alkylation on oxygen with a suitable reagent such as 4-benzylbenzyl bromide in the presence of K-.CO, in a solvent such as THF affords LXVII
  • Step 3 Benzyl (l -(2-hvdroxymethyl-5-phenylmethoxy)indolyl)formate
  • Step 4 Benzyl ( 1 -(2-bromomethyl-5-phenylmethoxy)indolyl)formate
  • Step 5 Benzyl (l-(2-(2-formylphenoxy)methyl-5-phenylmethoxy)indolyl)formate
  • Step 1 Benzyl ( l -(2-(2-(l -hvdroxy-2.2.2-tnfluoroethyl)phenoxy)methyl-5- phenylmetho ⁇ y) ⁇ ndolyl)-formate
  • step 2 l -(3-d ⁇ methylam ⁇ nopropyl)-3- ethylcarbodiimide (EDCI) (0.32 g, 1.66 mmol), 4-d ⁇ methylam ⁇ nopy ⁇ dme (DMAP) (0.018 g, 0.15 mmol) and ethyl 3-am ⁇ nobenzoate (0.27 g, 1.66 mmol) were stirred in tetrahydrofuran (9 mL) at room temperature overnight The next day the reaction was diluted with ethyl acetate and water, extracted with ethyl acetate (3X), d ⁇ ed over magnesium sulfate and concentrated.
  • EDCI l -(3-d ⁇ methylam ⁇ nopropyl)-3- ethylcarbodiimide
  • DMAP 4-d ⁇ methylam ⁇ nopy ⁇ dme
  • ethyl 3-am ⁇ nobenzoate 0.27 g, 1.66 mmol
  • Ethyl 5-methoxy-2- ⁇ ndolcarboxylate (30 g, 102 mmol) is dissolved in 250 mL of THF and cooled to 0° C and Lithium Aluminum Hydnde (LAH) (255 mL of a 1 0 M solution in THF) is added via addition funnel over 40 minutes The reaction was stirred a further 2 hours at 0° C and then worked up by the addition of 4N NaOH ( 190 mL) The resulting salts are filtered and washed with ethyl acetate (3X400 mL), the filtrates are combined and dned over MgSOj and concentrated to yield 24 8 g of alcohol, which was used for the next reaction directly
  • Step 4 3-(2-tert-butvd ⁇ methyls ⁇ lyloxymethyl-5-methoxy- l -methyl) ⁇ ndolyl (2,4-b ⁇ s( l , l - dimethvpropyl)phenoxy)methyl ketone
  • Step 6 Methyl 3-(2-(3-(2.4-bis(l ,l -dimethvpropyl)phenoxy)acetyl-5-methoxy-l - methylindolyl)methylthioacetamido)-4-methoxybenzoate
  • the indole alcohol, prepared in step 5, (0.20 g, 0.43 mmol) was dissolved in dichloromethane (0.7 mL) and treated with tnethylamine (0.1 mL, 0.64 mmol) and cooled to 0° C at which time mesyl chloride (0.04 mL 0.52 mmol) was added over 5 minutes, followed by addition of two drops of DMF.
  • T e reaction was stined for a further 2 hour at 0°C, it was then concentrated and used directly for the next reaction.
  • the above prepared mesylate was dissolved in DMF (0.8 mL). The solution was degassed by bubbling nitrogen through for ten min.
  • the carbamate, prepared in step 2 ( 15.25 g, 43 mmol) was dissolved in dichloromethane (180 mL) and treated with tnethylamine (9.0 mL, 64 4 mmol). The solution was cooled to -10° C at which time mesyl chlonde (4.3 mL. 56 mmol) was added over 5 minutes The reaction was stined for a further 2 hour at -10 °C, it was then concentrated and used directly for the next displacement reaction
  • Step 4 2-(5-Benzyloxy-l -tert-butoxycarbonyl) ⁇ ndol ⁇ nylmethylth ⁇ oacet ⁇ c acid
  • Step 7 Ethyl 3-f 2-f 5-benzyloxy- 1 -(2.4-bis( 1.1 - dimethyl)propyl)phenoxyacetyl)indolinv ⁇ methylthioacetamidobenzoate
  • step 7 The ester (0.231 g, 0.31 mmol) of step 7 was dissolved in THF (4.3 mL), methanol (4.3 L) and than IN NaOH (3.2 mL) was added.
  • N-tert-butoxycarbonyl indoline (3 0 g, 6 6 mmol), prepared in step 3 of Example 17, was added to a flask and cooled to 0 °C
  • t ⁇ fluoroacetic acid was added (35 mL) and the reaction was stired for 1 hour at 0 °C and then 1 hour at rt
  • the reaction was quenched by the addition of water, and the TFA was neutralized by the addition of solid sodium bicarbonate, the aqueous layer was extracted with ethyl acetate (4X) and dned over magnesium sulfate and concentrated to an orange oil (1.85 g, 79%) that was used directly for the next step
  • Step 2 Ethyl 2-(5-benzyloxy-l -(2.4-b ⁇ s(l , l -d ⁇ methv) ⁇ ropyl)phenoxyacetyl)- indolinylmethylthioacetate
  • Step 4 Methyl 3-(2-(5-benzyloxy- l -(2,4-b ⁇ s( 1.1- d ⁇ methv)propyl)phenoxyacetvh ⁇ ndol ⁇ nyl) methylth ⁇ oacetam ⁇ do-4-methylbenzoate
  • the titled compound was prepared from ester, prepared in step 4, according to the procedure desc ⁇ bed in step
  • Step 1 2-(5-Benzyloxy- 1 -(3.5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methanol
  • Step 2 Ethyl 2-(5-benzyloxy-l -(3.5-bis(trifluoromethyl)phenoxyacetyl)indolinyl) methylthioacetate
  • the titled compound was prepared according to the procedure desc ⁇ bed in step 2 of Example 38
  • Step 1 2-(5-Hvdroxy- 1 -(3,5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methanol
  • Step 2 2-(5-(4-Methoxy)benzyloxy-l -(3.5- bis(trifluoromethyl)phenoxyacetv ⁇ indolinyl)methanol
  • Step 3 Methyl 5-(2-(-5-(4-methoxy)benzyloxy- l -(3.5-bis(trifluoromethyl)phenoxyacetyl) indolinyl)methylthioacetamido)benzene- 1.3-dicarboxylate
  • the reaction mixture was heated at 70 °C for 2 h.
  • the reaction mixture was partitioned between AcOEt (30 mL) and H 2 0 (20 mL)
  • the aqueous layer was extracted with AcOEt (3 x 30 mL).
  • the combined AcOEt extracts were washed with b ⁇ ne (50 mL), d ⁇ ed over Na 2 S0 and filtered.
  • the solvents were removed in vacuo. Punfication of the residue by column chromatography on silica gel using 15% EtOAc in dichloromethane afforded 0 20 g of the product (77%)
  • the titled compound was prepared from the ester, prepared in step 1 , according to the procedure desc ⁇ bed in step 5 of Example 44
  • Step 1 Methyl 3-(2-(5-benzyloxyindolinvPmethylthioacetamido)-4-methoxybenzoate
  • This compound was prepared according to the procedures described in step 6 of Example 17. but with methyl 4-methoxybenzoate.
  • Step 2 Methyl 3-(2-(5-benzyloxy-l -(2-naphthoxyacetvPindolinvPmethylthioacetarnido)- 4-methoxybenzoate
  • Step 1 Ethyl 3-(2-(5-benzyloxy- l -tert-butoxycarbonyl) ⁇ ndol ⁇ nyl)methylsulfonyl acetamidobenzoate
  • the titled compound was prepared according to the procedure desc ⁇ bed in step 3 of Example 59
  • Step 1 5-Benzyloxy- 1 -(2.4-b ⁇ s( 1 , 1 -d ⁇ methv)propy PphenoxyacetvP-2- hvdroxymethylindohne
  • Step 2 2-(5-Benzyloxy- 1 -(2.4-b ⁇ s( 1.1 -d ⁇ methv)propyPphenoxyacetvP ⁇ ndol ⁇ nylmethyl methylsulfonate
  • the titled compound was prepared according to the procedure desc ⁇ bed in step 3 of Example 59.
  • EXAMPLE 68 was prepared according to the procedures desc ⁇ bed in Example 67
  • reaction mixture was st ed at 25 °C for 1 5 h to afford a pale suspension.
  • Methyl iodide 161 mg, 1.14 mmol was added, and the reaction mixture was stined at 25 °C for 2 days. After chilling to 0 °C, water was added ( 10 mL), followed by 50 L of half saturated ammonium chlonde, and 100 mL of EtOAc. The layers were separated, and the aqueous phase was extracted once with EtOAc (50 mL). The combined organic phases were d ⁇ ed (sodium sulfate), filtered, and concentrated to afford 0 6 g of crude product as an orange oil.
  • EXAMPLE 71 was prepared according to the procedures desc ⁇ bed in Example 70. but using allyl bromide.
  • the titled compound was prepared according to the procedure descnbed in step 3 of Example 59.
  • Step 1 Ethyl 3-(2-(5-benzyloxy-l -(2- naphthvPmethv) ⁇ ndol ⁇ nyl)methylth ⁇ oacetam ⁇ dobenzoate
  • the titled compound was prepared according to the procedure described in step 3 of Example 59.
  • Step 1 2-(2-(-5-Benzyloxy- 1 -( 1.1 -dimethvPethoxycarbonvPindolinyl )methyl methylsulfonate
  • tert-Butyl l -(5-benzyloxy-2-hydroxymethy)lindolinylformate (6.72 g, 19 mmol), prepared in step 2 of Example 17, was dissolved in CH 2 C1 (80 mL, dried over MgS0 4 before use). The clear yellow solution was cooled in a dry-ice bath. Et,N (4.0 mL) was then added followed by methanesulfonyl chloride (2.0 mL). The reaction mixture was stined for 2 h at -40 °C then quenched with H 2 0. It was washed with satuarated NaHC0 3
  • Step 2 Methyl 2-(2-(5-Benzyloxy-l-(l .l-dimethyl)ethoxycarbonvPindolinvPmethylthio benzoate
  • Step 4 Methyl 2-(2-(5-Benzyloxy- l -(4-benzvPbenzvPindolinyl)methylthiobenzoate
  • ester ( 1 g), prepared in step 3 was dissolved in
  • Step 2 Methyl 4-( l -(5-Benzyloxy-2-(b ⁇ s-2,4-tnfluoromethyl)ben7yloxymethyl) ⁇ ndol ⁇ nyl) methylbenzoate
  • the titled compound was prepared according to the prodedure desc ⁇ bed in step 5 of Example 76
  • Step 1 2-(l -(2.4-Bis(trifluoromethvPbenzyl)indolinyl)carboxylic acid
  • N-Methylsulfonyl-2-(l -(2.4-bis(trifluoromethvPbenzvPindol ⁇ nyl)carboxamide The acid (0 13g, 0 32 mmol), prepared in step 1 of Example 83, EDCI (0 07 g, 0 39 mmol), DMAP (4 mg, 0.03 mmol) and methylsuifonanihde (004 g, 0 39 mmol) were dissolved THF (5 mL) and refluxed 16 hours which yielded after workup (0 16 g), punfication via Chromatography (98 2 dichloromethane methanol) yielded 0 04 g of the titled compound (29%)
  • the titled compound was prepared according to the prodedure desc ⁇ bed in Example 84, but using phenylsulfonylamide
  • Step 3 2-Trimethylsilylethyl l -(5-(4-methoxy)benzyloxy-2- hvdroxymethvPindolinylformate
  • Step 4 2-Trimethylsilylethyl l -(5-(4-methoxy)benzyloxy-2- bromomethvPindolinylformate
  • Step 6 2-Trimethylsilylethyl l -(5-(4-methoxy)benzyloxy-2- aminomethvDindolinylformate
  • Step 7 Methyl 5-(2-(5-Methoxybenzyloxy- l -(2- trimethylsilyloxy)ethoxycarbonv)lindolinyl) methylaminocarboxamido-1.3- benzenedicarboxylate
  • Step 9 Methyl 5-(2-(5-Methoxybenzyloxy- l -(b ⁇ s-2.4-tnfluoromethyl)benzvP ⁇ ndol ⁇ nvP eth ylaminocarboxamido- 1.3-benzened ⁇ carboxylate
  • EXAMPLE 87 was prepared according to the prodedure desc ⁇ bed in Example 86. but using 4-(3,5-b ⁇ s(tnfluoromethyl)phenoxymethyl)benzyl bromide.
  • Step 1 B ⁇ s(methyl 4-methoxy-3-d ⁇ th ⁇ oacetam ⁇ dobenzoate)
  • the titled compound was synthesized according to the procedures desc ⁇ bed in
  • the reaction mixture was cooled to -78°C again and added 4-methoxyphenylacet ⁇ c acid (50 g, 0.28 mol) dropwise via the dropping funnel After stirnng at -50 °C for 1 h., the reaction mixture was allowed to warm to -30 °C over 20 min and then cooled to -50 °C again The reaction mixture was quenched with H 2 0 (500 mL) at -50 °C and warmed up to room temperature and stmed for 0 5 h The reaction mixture was partitioned between CH 2 C1 2 (500 mL) and H,0 The aqueous layer was extracted with CH,CI, (3 x 500 mL) The combined CH 2 C1 2 extracts were concentrated in vacuo to give a yellow oil This was added slowly to a 2 M solution of NaOH (2 L) cooled at 0 °C and stined at room temperature overnight The reaction mixture was partitioned between CH 2 CL (500 mL) and H 2 0 The aqueous layer was
  • a 10-mL oven-dned round bottom flask fitted with a magnetic stimng bar was charged with alcohol (0.30 g, 1.24 mmol), prepared in step 2, Ag 2 0 (0 68 g, 3.0 mmol) and toluene (3 mL). To this was added CH,I (0.36 g, 5 75 mmol) dropwise. The reaction flask was capped tightly and placed into a sonication chamber. The reaction mixture was sonicated for 18 h while stirnng at room temperature.
  • reaction mixture was filtered through Celite and concentrated in vacuo to dryness
  • residue was pu ⁇ fied by column chromatography on silica gel (eluant: 30% AcOEt in hexane) to afford desired product Yield 0.26 g (82%).
  • reaction flask was placed under vacuum via the water aspirator and subsequently filled with H 2 This was repeated three times The reaction mixture was stmed for 18 hours under positive H 2 pressure until all starting matenal was reacted The reaction mixture was filtered through Cehte and concentrated in vacuo to dryness The residue was punfied by column chromatography on silica gel using 10% ethyl acetate in dichloromethane to afford the titled compound (0.57 g, 97%)
  • the titled compound was prepared from nitro compound, prepared in step 1 of Intermediate 3, according to the procedure desc ⁇ bed in step 4 of Intermediate 3 INTERMEDIATE 6
  • the reaction mixture was partitioned between CH 2 C1 2 (50 L) and H 2 0 (50 mL)
  • the aqueous layer was extracted with CH 2 C1, (3 x 50 mL).
  • the combined CH 2 C1 2 extracts were washed with b ⁇ ne (50 mL), d ⁇ ed over Na 2 S0 4 and filtered.
  • the solvents were removed in vacuo. Punfication by column chromatography on silica gel (eluant: 30% AcOEt in hexane) afforded 0 7 g of product (58%).
  • the titled compound was prepared from nitro compound, prepared in step 1 , according tothe procedure descnbed in step 4 of Intermediate 3.
  • This compound was synthesized form ester, prepared in step 1 of Intermediate 3, according to the procedure descnbed in step 1 of Intermediate 6, but using allyl bromide.
  • the titled compound was prepared from 4-benzylphenol according to the procedure descnbed in of Intermediate 8.
  • the titled compound was prepared from 2-naphthol according to the procedure desc ⁇ bed in of Intermediate 8.
  • the titled compound was prepared from 3,5-b ⁇ s(t ⁇ fluoromethyl)phenol according to the procedure desc ⁇ bed in of Intermediate 8.
  • Step 1 Methyl 5-n ⁇ tro-3-(N.N-d ⁇ methvPcarbamoylbenzoate
  • a 100-mL oven-dned round bottom flask fitted with a magnetic stimng bar was charged with 5-mtro-3-methoxycarbonylbenzo ⁇ c acid (3.15 g, 10 mmol), DMF ( 1 drop), anhydrous CH 2 C1 2 (70 L), and oxalyl chlonde (3.7 mL, 42.3 mmol).
  • the reaction mixture was stined at room temperature for 2 h.
  • the solvent was removed in vacuo to afford acid chlo ⁇ de as a white solid. This was used immediately in the next step without further punfication.
  • the titled compound was prepared from nitro compound, prepared in step 1 , according to the procedure desc ⁇ bed in step 4 of Intermediate 3.
  • the titled compound was prepared from nitro compound, prepared in step 1 , according to the procedure desc ⁇ bed in step 4 of Intermediate 3
  • the titled compound was prepared from nitro compound, prepared in step 2, according to the procedure described in step 4 of Intermediate 3.
  • Step 2 B ⁇ s-( methyl 4-methoxy-3-(2-dith ⁇ oethyl)am ⁇ nobenzoate
  • a typical assay consisted of the lipid mixture (85 ⁇ l) to which was added consecutively, the inhibitor (5 ⁇ l in DMSO) and cPLA 2 , 10 ng for an automated system or 1 ng for a manual assay, in lO ⁇ l of the BSA buffer. This assay was conducted by either the manual assay or automated assay protocol described below.
  • the lipid suspension and inhibitor were pre-incubated for 7 min. at 37°C. Enzyme was added and the incubation was continued for a further 30 mins. The reaction was then quenched by the addition of decane: isopropanol: trifluoroacetic acid (192:8: 1 w/v, 150 ⁇ l). A portion of the quench layer (50 ⁇ l) was passed through a Rainin Spheric-5 silica column
  • PMNs were isolated using Ficoll-Hypaque according to the manufacturers directions. Red blood cells contaminating the PMNs were removed by hypotonic lysis, and the PMN pellet was washed once, and resuspended in Hanks buffered saline at a concentration of 2 x 10 6 cells/ml. The cells were preincubated with inhibitors for 15 min at 37 °C and then stimulated with 2 uM A23187. When monitoring LTB 4 production as a measure of cPLA 2 inhibition, the reaction was quenched with an equal volume of ice cold phosphate buffered saline. Cells were removed by centrifugation, and the LTB 4 present in the cell supernatant was measured using the LTB scintillation proximity assay provided by
  • RBL-2H3 cells were routinely cultured as 37°C in a 5% C0 2 atmosphere in minimal essential medium containing nonessential amino acids and 12% fetal calf serum The day before the expenment, cells were seeded into spinner flasks at 3 x ⁇ 0 cells/ml and 100 ng/ml DNP specific-IgE was added After 20 hrs, the cells were harvested by centnfugation and washed once in serum-free minimal essential media, and resuspended to 2 x 10 6 ceils/ml in serum free media The cells were then premcubated with either inhibitor in DMSO (1 % v/v) or DMSO ( 1 % v/v) for 15 min at 37°C followed by stimulation with DNP-BSA (300 ng/ml) After 6 min, the cells were removed by centnfugation, and the supernatant was assayed for PGD 2 content in accordance with known methods

Abstract

Compounds having a chemical formula selected from the group consisting of formulae (I), (II) and (III) or a pharmaceutically acceptable salt thereof, wherein: A is independent of any other group and is selected from the group consisting of -CH2- and -CH2-CH2-; B is independent of any other group and is selected from the group consisting of -(CH2)n-, -(CH2O)n-, -(CH2S)n-, -(OCH2)n-, -(SCH2)n-, -(CH=CH)n-, -(C C)n-, -CON(R6)-, -N(R6)CO-, -O-, -S- and -N(R6)-; R2 is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR5, -CONR5R6, -(CH2)n-W-(CH2)m-Z-R5, -(CH2)n-W-R5, -Z-R5, C1-C10 alkyl, alkenyl and substituted aryl; R3 is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR5, -CONR5R6, -(CH2)n-W-(CH2)m-Z-R5, -(CH2)n-W-R5, -Z-R5, C1-C10 alkyl, alkenyl and substituted aryl; which inhibit the activity of phospholipase enzymes, particularly cytosolic phospholipase A2. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.

Description

INHIBITORS OF PHOSPHOLIPASE ENZYMES Background of the Invention
The present invention relates to chemical inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A, enzymes.
Leukotrienes and prostaglandins are important mediators of inflammation. Leukotrienes recruit inflammatory cells such as neutrophils to an inflamed site, promote the extravasation of these cells and stimulate release of superoxide and proteases which damage the tissue. Leukotrienes also play a pathophysiological role in the hypersensitivity experienced by asthmatics [See, e.g. B. Samuelson et al., Science. 227: 1 171-76 ( 1987)].
Prostaglandins enhance inflammation by increasing blood flow and therefore infiltration of leukocytes to inflamed sites. Prostaglandins also potentiate the pain response induced by stimuli. Prostaglandins and leukotrienes are unstable and are not stored in cells, but are instead synthesized [W. L. Smith, Biochem. J.. 259:315-324 (1989)] from arachidonic acid in response to stimuli. Likewise arachidonic acid is not free in cells but is released from the sn-2 position of membrane phospholipids by phospholipase A: (hereinafter PLA2). The reaction catalyzed by PLA2 is believed to represent the rate-limiting step in the process of lipid mediated biosynthesis. When the phospholipid substrate of PLA, is of the phosphotidyl choline class with an ether linkage in the sn- 1 position, the lysophospholipid produced is the immediate precursor of platelet activating factor (hereafter called PAF), another potent mediator of inflammation [S.I. Wasserman, Hospital Practice, 15:49-58 ( 1988)]. Consequently the direct inhibition of the activity of PLA; has been suggested as a useful mechanism for a therapeutic agent, i.e.. to interfere with the inflammatory response. [See, e.g., J. Chang et al, Biochem. Pharmacol.. 36:2429-2436 (1987)]. A family of PLA-, enzymes characterized by the presence of a secretion signal sequenced and ultimately secreted from the cell have been sequenced and structurally defined. These secreted PLA,s have an approximately 14 kD molecular weight and contain seven disulfide bonds which are necessary for activity. These PLA,s are found in large quantities in mammalian pancreas, bee venom, and various snake venom. [See, e.g., references 13-15 in Chang et al, cited above; and E. A. Dennis, Drug Devel. Res.. 10:205-
220 (1987).] However, the pancreatic enzyme is believed to serve a digestive function and, as such, should not be important in the production of the inflammatory mediators whose production must be tightly regulated.
The primary structure of the first human non-pancreatic PLA: has been determined. This non-pancreatic PLA: is found in platelets, synovial fluid, and spleen and is also a secreted enzyme This enzyme is a member of the aforementioned family [See, J J Seilhamer et al. J Biol Chem . 264 5335-5338 (1989). R M Kramer et al. J Biol Chem . 264 5768-5775 (1989), and A Kando et al, Biochem Biophvs Res Comm . 163 42-48 (1989)] However, it is doubtful that this enzyme is important in the synthesis of prostaglandins, leukotrienes and PAF, since the non-pancreatic PLA2 is an extracellular protein which would be difficult to regulate, and the next enzymes in the biosynthetic pathways for these compounds are intraceliular proteins Moreover, there is evidence that PLA2 is regulated by protein kinase C and G proteins [R Burch and J Axelrod, Proc Natl Acad Sci U S A . 84 6374-6378 (1989)] which are cytosolic proteins which must act on intraceliular proteins It would be impossible for the non-pancreatic PLA2 to function in the cytosol, since the high reduction potential would reduce the disulfide bonds and inactivate the enzyme
A muπne PLA-, has been identified in the muπne macrophage cell line, designated RAW 264 7 A specific activity of 2 μmols/min/mg, resistant to reducing conditions, was reported to be associated with the approximately 60 kD molecule However, this protein was not puπfied to homogeneity [See, C C Leslie et al, Biochem Biophvs Acta . 963 476-492 (1988)] The references cited above are incorporated by reference herein for information pertaining to the function of the phospholipase enzymes, particularly PLA2 A cytosolic phospholipase A2 (hereinafter "cPLAi") has also been identified and cloned See, U S Patent Nos 5,322,776 and 5,354,677, which are incorporated herein by reference as if fully set forth The enzyme of these patents is an intraceliular PLA2 enzyme, puπfied from its natural source or otherwise produced in puπfied form, which functions intraceilularly to produce arachidonic acid in response to inflammatory stimuli
Now that several phospholipase enzymes have been identified, it would be desirable to identify chemical inhibitors of the action of enzymes, which inhibitors could be used to treat inflammatory conditions. However, there remains a need in the art for an identification of effective anti-inflammatory agents for therapeutic use in a vaπety of disease states
Summary of the Invention
The present invention provides compounds having a chemical formula selected from the group consisting of:
Figure imgf000005_0001
Figure imgf000005_0002
or a pharmaceutically acceptable salt thereof, wherein:
A is independent of any other group and is selected from the group consisting of -CH2- and -CH2-CH2-;
B is independent of any other group and is selected from the group consisting of -(CH2)n-, -(CH20)n-, -(CH2S)n-, -(OCH2)n-, -(SCH2)n-, -(CH=CH)n-, -(C≡C)n-, -CON(R6)-, -N(R6)CO-, -0-, -S- and -N(R6)-;
R, is independent of any other R group and is selected from the group consisting of -X-R6, -H. -OH, halogen, -CN, -N02, C,-C, alkyl, alkenyl, alkinyl, aryl and substituted aryl;
R2 is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR,, -CONR,R6, -(CH2)n-W-(CH2)m-Z-R„ -(CH2)„-W-R„ -Z-R„ C,-C,0 alkyl, alkenyl and substituted aryl;
R, is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR5, -CONR,R6, -(CH2)n-W-(CH2)m-Z-Rs, (CH2)n-W-R„ -Z-R„ CrCl0 alkyl, alkenyl and substituted aryl;
R4 is independent of any other R group and is selected from the group consisting of -H, -OH, -OR6, -SR6, -CN, -COR6, -NHR6, -COOH, -CONR6R7, -N02, -CONHS02RR, C,- C5 alkyl, alkenyl and substituted aryl;
R, is independent of any other R group and is selected from the group consisting of -H, -OH, -0(CH2)nR6, -SR6, -CN, -COR6, -NHR6, -COOH, -N02, -COOH, -CONRήR7, -CONHSO:R8, CrC, alkyl, alkenyl, alkinyl, aryl, substituted aryl, -CF„ -CF,CF, and
Figure imgf000006_0001
R6 is independent of any other R group and is selected from the group consisting of -H, C,-C3 alkyl, alkenyl, alkinyl, aryl and substituted aryl,
R7 is independent of any other R group and is selected from the group consisting of -H, C,-C, alkyl, alkenyl, alkinyl, aryl and substituted aryl,
R8 is independent of any other R group and is selected from the group consisting of C,-C3 alkyl, aryl and substituted aryl,
R, is independent of any other R group and is selected from the group consisting of -H, -OH, a halogen, -CN, -OR6, -COOH, -CONR6R7, tetrazole, -CONHS02R8, -CORή, -(CH2)nCH(OH)R6 and -(CH2)nCHR6R„
Rι0 is independent of any other R group and is selected from the group consisting of -H, -OH, a halogen, -CN, -OR6, -COOH, -CONR6R7, tetrazole, -CONHS02R8, -COR6, -(CH2)„CH(OH)R6 and -(CH2)nCHR6R5,
W is, independently each time used including within the same compound, selected from the group consisting of -0-, -S-, -CH,-, -CH=CH-, -C ≡ C- and -N(R6)-,
X is independent of any other group and is, independently each time used including within the same compound, selected from the group consisting of -O-, -S- and -N(R6)-,
Z is independent of any other group and is, independently each time used including within the same compound, selected from the group consisting of -CH2-, -0-, -S-, -N(R6)-, - CO-, -CON(R6)- and -N(R„)CO-, m is, independently each time used including within the same compound, an integer from 0 to 4, and n is independent of m and is, independently each time used including within the same compound, an integer from 0 to 4
Preferably, the compounds of the invention have phospholipase enzyme inhibiting activity Other preferrred embodiments include compounds having the following chemical formula
Figure imgf000006_0002
compounds having the following chemical formula:
Figure imgf000007_0001
compounds having the following chemical formula:
Figure imgf000007_0002
In particularly preferred embodiments, A is -CH2- and R2 is
-(CH2)n-W-(CH2)m-ZR<j These preferred compounds includes those wherein n is 1 , is 1 , W is -S- and Z is -CO-; those wherein R5 is -NHR6; those wherein R6 is a substituted aryl group and those wherein said aryl group is substituted with one or more substituents independently selected from the group consisting of a halogen, -CF3, -CF2CF3, -(CH2)pCOOH, -(CH2)pCH3, -0(CH2)pCH„ -(CH2)pOH, -(CH2)pS(C6H6),
-(CH2)pCONH2 and -CHRMCOOH, wherein Rπ is selected froup the group consisting of alkyl, alkenyl, alkynyl, -(CH2)pOH, and -0(CH2)pCH3, and wherein p is an integer from 0 to 4. Other preferred comounds include those wherein R, is selected from the group consisting of -H and -OCH2(C6H6) and R, is -COR , R5 is -OCH2R6 and R6 is a substituted aryl group. In particularly preferred compounds, said aryl group is substituted with one or more substituents selected from the group consisting of -CF3, -CF2CF3 and -C(CH,)2CH2CH3.
The present invention also provides for a method of inhibiting the phospholipase enzyme activity of an enzyme, comprising administering to a mammalian subject a therapeutically effective amount of a compound of the present invention. Methods of treating an inflammatory condition, comprising administering to a mammalian subject a therapeutically effective amount of a compound of the present invention are also provided. Pharmaceutical compositions comprising compounds of the present invention and a pharmaceutically acceptable carrier are also provided. Pharmaceutically acceptable salts of the compounds of the compounds descπbed herein are also part of the present invention and may be used in practicing the compounds and methods disclosed herein.
Bπef Description of the Figures
Figs. 1 -13 depict schemes for synthesis of compounds of the present invention. The depicted schemes are descπbed in further detail below.
Detailed Descnption of Preferred Embodiments As used herein: "halogen" includes chloπne, fluorine, iodine and bromine; "alkyl",
"alkenyl" and "alkinyl" include both straight chain and branched moieties; "aryl" includes single and multiple πng moieties; and "substituted" denotes the presence of one or more similar ot dissimilar substituent groups of any character.
Preferred compounds of the present invention are disclosed in Tables I-VI below Methods for synthesis of the compounds listed in Tables I-VI are descπbed below.
Compound Nos. in the tables correspond to example numbers below describing synthesis of that particular compound.
Tables I-VI also report data for the listed compounds in the "LysoPC" assay and the Coumarine assay (see Example 88 below). In the data columns of the tables, assay results are reported as an "IC50" value, which is the concentration of a compound which inhibits 50% of the activity of the phospholipase enzyme in such assay. Where no numeπcal IC50 value appears, "NA" denotes that inhibitory activity was not detected from such compound in the corresponding assay and a blank box denotes that the compound was not tested in such assay as of the time of filing of the present application
Figure imgf000009_0001
Figure imgf000010_0002
Figure imgf000010_0001
Figure imgf000010_0003
Figure imgf000011_0003
Figure imgf000011_0001
Figure imgf000011_0002
Figure imgf000012_0001
SUBSTITUTE SHEET (RULE 26)
Figure imgf000013_0002
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000015_0002
Figure imgf000016_0001
Figure imgf000016_0002
oo m
fN rn
CN
Figure imgf000017_0001
Figure imgf000017_0002
oo
CN rt
Figure imgf000018_0001
Figure imgf000018_0002
Figure imgf000019_0001
Figure imgf000019_0002
Figure imgf000020_0001
Figure imgf000020_0002
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
o >n Λ
rt rr
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0002
Figure imgf000027_0001
Figure imgf000028_0002
Figure imgf000029_0002
Figure imgf000029_0001
fN co o
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000032_0002
Figure imgf000033_0001
Figure imgf000033_0002
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000035_0002
Figure imgf000036_0001
Compounds of the present invention were also tested for in vivo activity in a rat paw edema test according to the procedure descπbed in Example 89 The results are reported in Table VII
Table VII
Figure imgf000037_0001
As used herein, "phospholipase enzyme activity" means positive activity in an assay for metabolism of phospholipids (preferably one of the assays descπbed in Example 88 below). A compound has "phospholipase enzyme inhibiting activity" when it inhibits the activity of a phospholipase (preferably cPLA2) in any available assay (preferably an assay descπbed below in Example 88 or Example 89) for enzyme activity In preferred embodiments, a compound has ( 1 ) an ICS0 value of less than about 25 μM, preferably less than about 6 μM, in the LysoPC assay, (2) an ICS0 value of less than about 50 μM in the vesicle assay; (3) an IC<;o value of less than about 1 μM in the PMN assay, (4) an IC50 value of less than about 15 μM in the Coumaπne assay, and/or (5) measurable activity (preferably at least about 5% reduction in edema, more preferably at least about 10% reduction) in the rat carrageenan-induced footpad edema test
Compounds of the present invention are useful for inhibiting phospholipase enzyme (preferably cPLA,) activity and, therefore, are useful in "treating" (I e., treating, preventing or ameliorating) inflammatory or inflammation-related conditions (e.g., rheumatoid arthπtis, psoπasis, asthma, inflammatory bowel disease, and other diseases mediated by prostaglandins, leukotπenes or PAF) and other conditions, such as osteoporosis, colitis, myelogenous leukemia, diabetes, wasting and atherosclerosis The present invention encompasses both pharmaceutical compositions and therapeutic methods of treatment or use which employ compounds of the present invention
Compounds of the present invention may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable earner Such a composition may also contain (in addition to a compound or compounds of the present invention and a earner) diluents, fillers, salts, buffers, stabilizers, solubihzers, and other mateπals well known in the art The term "pharmaceutically acceptable" means a non-toxic mateπal that does not interfere with the effectiveness of the biological activity of the active ιngredιent(s) The characteπstics of the earner will depend on the route of administration. The pharmaceutical composition may further contain other anti-inflammatory agents Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with compounds of the present invention, or to minimize side effects caused by the compound of the present invention
The pharmaceutical composition of the invention may be in the form of a liposome in which compounds of the present invention are combined, in addition to other pharmaceutically acceptable earners, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution Suitable lipids for hposomal formulation include, without limitation, monoglyceπdes, diglyceπdes, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like Preparation of such hposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S Patent No 4,235,871 , U.S Patent No 4,501 ,728, U S Patent No 4,837,028, and U S Patent No 4,737,323, all of which are incorporated herein by reference
As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, l e , treatment, healing, prevention or amelioration of an inflammatory response or condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, seπally or simultaneously
In practicing the method of treatment or use of the present invention, a therapeutically effective amount of a compound of the present invention is administered to a mammal having a condition to be treated Compounds of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing other anti-inflammatory agents, cytokines, lymphokines or other hematopoietic factors When co-administered with one or more other anti-inflammatory agents, cytokines, lymphokines or other hematopoietic factors, compounds of the present invention may be administered either simultaneously with the other anti-inflammatory agent(s), cytokιne(s), lymphokιne(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially If administered sequentially, the attending physician will decide on the appropπate sequence of ad inisteπng compounds of the present invention in combination with other anti- lnflammatory agent(s), cytokme(s), lymphokιne(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors Administration of compounds of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be earned out in a vanety of conventional ways, such as oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection
When a therapeutically effective amount of compounds of the present invention is administered orally, compounds of the present invention will be in the form of a tablet, capsule, powder, solution or elixir When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid earner such as a gelatin or an adjuvant The tablet, capsule, and powder contain from about 5 to 95% compound of the present invention, and preferably from about 25 to 90% compound of the present invention When administered in liquid form, a liquid earner such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil. soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene giycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of compound of the present invention, and preferably from about 1 to 50% compound of the present invention.
When a therapeutically effective amount of compounds of the present invention is administered by intravenous, cutaneous or subcutaneous injection, compounds of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to compounds of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium
Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art. The amount of compound(s) of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of compound of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of compound of the present invention and observe the patient's response. Larger doses of compounds of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.1 μg to about 100 mg of compound of the present invention per kg body weight. The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the compounds of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
Methods of Synthesis Compounds of the present invention can be prepared according to the following methods. Temperatures are in degrees Celsius. METHOD A
Indol-2-carboxylic acid ethyl ester I is converted to aldehyde II in two steps: reduction with lithium aluminum hydride (LAH) or other hydride in a suitable solvent such as tetrahydrofuran (THF) at 0 °C, and then oxidation with an oxidizing reagent such as manganese dioxide in a solvent such as THF. Deprotonation of aldehyde II with a strong base such as potassium hexamethyldisilyl amide (KHMDS) in THF, followed by reaction with a chloroformate in the presence of a base, such as triethyl amine, produces carbamate III. Ill is transformed into bromide IV in two steps: (1 ) reduction with sodium borohydride in an alcoholic solution and (2) reaction withcarbon tetrabromide in the presence of a phosphine reagent such as bis(diphenylphosphino)propane in dichloromethane. Displacement of the bromine in IV with potassium phenoxide, prepared by reaction of a phenol with KHMDS, in a suitable solvent such as THF or DMF affords ether V. V can be converted to either trifluoromethyl ketone VII or to carboxylic acid IX in different procedures. Reaction of V with trifluoromethyl trimethylsilane (TMSCF3) in the presence oftetrabutylammonium fluoride gives trifluoromethyl alcohol, which is then oxidized with periodinane (Dess-Martin reagent) in dichloromethane to afford ketone VI. In this stage the carbamate can be removed with either trifluoroacetic acid (TFA) or with a base such as sodium hydroxide. The indole nitrogen is then alkylated with a suitable alkyl bromide in the presence of a base such as sodium hydride to produce VII. Alternatively, V can be deprotected with TFA or aqueous base, and then reacted with alkyl bromide to give VIII, which is oxidized with sodium chlorite in an aqueous THF to yield acid IX.
METHOD B
2-Indolyl carboxylic acid ethyl ester I is deprotonated with a strong base such as sodium hydride (NaH) in THF, and then reacted with a suitable alkyl bromide to give X. Hydrolysis of X with a aqueous base such as sodium hydroxide and reaction with aniline or a substituted aniline in the presence of a carbodiimide such as dimethylaminopropyl ethylcarbodiimide hydrochloπde (EDCI) in a suitable solvent such as dichloromethane affords amide XI XI is hydrolyzed to corresponding acid XII in a aqueous base such as sodium hydroxide
METHOD C
Indole I can be brominated on the 3-posιtιon by reaction with a bromine or N- bromosucciπimide in a suitable solvent such ascarbon tetrachloπde or dichloromethane to yield bromide XIII Reaction of XIII with a suitable alkyl bromide in the presence of a strong base such as NaH in THF or DMF affords indole XIV Palladium mediated coupling of XIV with a suitable alkene in the presence of phosphine and a base such as tπethyl amine produces 3-substιtuted indole XV XV can be converted to amide XVII in two step reactions ( 1 ) hydrolysis with aqueous base such as NaOH and (2) coupling with an amine in the presence of carbodiimide such as EDCI Ester XIV can be transformed to lithium salt XVIII by hydrolysis with aqueous base and then reaction with lithium hydroxide in a suitable solvent such as ether Lithiation with n-butyl lithium in a suitable solvent such as THF, and then acylation with an acyl chloπde in THF affords ketone XIX
Carbodiimide (EDCI) catalyzed coupling of XIX and a suitable amine gives amide XX
METHOD D
Indole I can be converted to XXI in two steps ( 1 ) reduction with LAH in a solvent such as
THF and (2) silylation with t-butyldimethylsilyl chloπde (TBDMSC1) in a solvent such as dichloromethane or DMF in the presence of a base such as imidazole Treatment of XXI with Gπgnard reagent such as ethyl magnesium bromide m a solvent such as THF at -60 °C, acylation of the resulting magnesium salt with a suitable acyl chloπde such as acetyl chloπde in ether and finally, alkylation on the nitrogen with an alkyl halide such as ethyl bromide in the presence of a strong base such as NaH in DMF affords ketone XXII The silyl group on XXII is removed using tetrabutylammonium fluoπde in a solvent such THF, the resulting alcohol is then converted to bromide using carbon tetrabromide and bιs(dιphenylphosphιno)ethane in a solvent such as dichloromethane to yield bromide XXIII Displacement of the bromine of XXIII with a thiol compound in the presence of a base such as Cs O,, or with an alcohol in the presence of a strong base such as NaH in DMF affords XXIV (sulfide, or ether respectively)
METHOD E
Aldehyde II, prepared by Method A, can be alkylated by a suitable alkyl bromide (or iodide), such as benzyl bromide or ethyl iodide in the presence of a strong base such as sodium hydnde or KHMDS in a solvent such as DMF to yield XXV XXV can be converted to an unsaturated acid XXVI by two steps (1 ) Wittig reaction with a suitable reagent such as tπmethyl phosphonoacetate in the presence of a base such as sodium hydnde in a solvent such as THF and (2) Hydrolysis by aqueous sodium hydroxide Coupling reaction of XXVI with an amine catalyzed by a dnmide such as EDCI (dimethylaminopropyl ethylcarbodnmide hydrochloπde), followed by hydrolysis with aqueous base such as sodium hydroxide affords XXVII.
METHOD F
Indole I is reduced with LAH in a solvent such as THF A second reduction with sodium cyanoborohydπde in a solvent such as acetic acid to yield alcohol XXVIII Protection of the nitrogen of XXVIII with t-butoxycarbonyl (BOC) using di-t-butyldicarbonate ((BOC)30) in the presence of a base such as tnethylamine affords carbamate XXIX The hydroxyl group in XXIX is mesylated using mesyl chloπde and tnethylamine in a solvent such as dichloromethane, and then displaced by either a thiol or an alcohol as descπbed in
METHOD D to produce indohne XXX Deprotection of XXX using tπfluoroacetic acid affords XXXI, which is either acylated (acyl chloπde, tnethylamine, dichloromethane) or alkylated (alkyl ha de, K2CO DMF) to afford XXXII, or XXXIII respectively
METHOD G
Carboxylic acid XXXIV is converted to aldehyde XXXV in two steps ( 1) reaction with N.O-dimethylhydroxy amine in the presence of EDCI in a solvent such as dichloromethane, and (2) reduction with diisobutyl aluminum hydride (DIBAL) in a solvent such as THF. Treatment of XXXV with trimethyl phosphonoacetate in the presence of a strong base such as KHMDS in a solvent such as THF results in the formation of ester XXXVI. Reduction of XXXVI with tin in hydrogen chloride, followed by cyclization in a heated inert solvent such as toluene gives XXXVII. Alkylation on nitrogen of XXXVII under conditions described in METHOD F, and then hydrolysis of the ester with aqueous base such as NaOH affords acid XXXVIII. XXXVIII can be converted to an amide XXXIX by coupling with a suitable amine such as benzylamine in the presence of EDCI.
METHOD H
Aldehyde XXXV, prepared in METHOD G, is subjected to a Wittig reaction using methyl triphenylphosphonium iodide in the presence of a strong base such as KHMDS or NaH in a solvent such as THF to afford alkene XL. Reduction of the nitro group of XL with iron powder in an ammonium chloride solution, followed by treatment with benzyl chloroformate in the presence of a base such as triethyl amine produces carbamate XLI. XLI is treated with iodine in a basic solution such as aqueous NaHCO, in THF to yield iodide XLII. Displacement of the iodine on XLII with lithium benzoate in a solvent such as DMF, followed by hydrolysis with NaOH affords alcohol XLIII.
METHOD I
Indoline XXVIII, prepared in METHOD F or METHOD H. can be either acylated by reaction with an acyl chloride in the presence of a base such as triethyl amine or alkylated using alkyl halide in the presence of K-jCO, in a solvent such as DMF to produce alcohol XLIV. Treatment of XLIV with mesyl chloride and triethyl amine in a solvent such as dichloromethane, followed by displacement with a thiol such as methyl mercaptoacetate in the presence of a base such as Cs3CO, in a solvent such as acetonitrile yields ester XLV. Hydrolysis of XLV with an aqueous base such as NaOH gives acid XLVI, which can be coupled with an amine catalyzed by a diimide such as EDCI in a solvent such as dichloromethane to afford amide XLVII. XLVII can be alkylated on the amide nitrogen by treatment with alkyl halide and strong base such as NaH in DMF Hydrolysis of the resulting amide with aqueous base such as NaOH gives acid XLIX XLIV can also be directly hydrolyzed with NaOH to a carboxylic acid XLVIII
METHOD J
METHOD J illustrates the synthesis of alpha-substituted aminophenylacetic acid esters Ester L can be deprotonated with a strong base such as lithium dnsobutylamide (LDA) in a solvent such as THF, and subsequently alkylated with an alkyl halide such as methyl iodide to give LI Reduction of LI to amine LIII can be accomplished using hydrogenation catalyzed by palladium in a solvent such as ethanol L can be oxidized to alcohol LII using LDA and oxazindine in a solvent such as THF Alkylation of LII with a alkylating reagent such as methyl iodide in the presence of a strong base such as NaH in DMF, followed by catalytic hydrogenation in the presence of palladium produces amine LIV
METHOD K
METHOD K illustrates the synthesis of substituted aminobenzoic acid esters Mono-acid LV can be converted to amide LVI by the following steps' (1) reaction with oxalyl chloπde in dichloromethane to form acid chloπde and (2) treatment with a suitable amine such as dimethyl amine Reduction of the nitro group to the amine is accomplished with hydrogenation catalyzed by palladium as descπbed in METHOD J LV can be reduced to alcohol LVIII with hydroborane-THF complex in THF Protection of the hydroxy group as a silyl ether using TBDMSCI in the presence of lmidazole and subsequently, reduction of the nitro group (H2 / Pd-C) to the amine affords LIX LVIII can be converted to the secondary alcohol LX in two steps. ( I ) oxidation with a suitable reagent such as manganese dioxide (Mn02) in ethyl acetate and (2) addition of a desired Gπgnard reagent such as methyl magnesium bromide in THF Oxidation of LX with MnO, in THF and reduction of the nitro group (H2 / Pd-C) produces ketone LXIII. Reduction of LVII (H, / Pd-C) yields LXI. METHOD L
Alcohol LXrV, prepared in METHOD I, can be debenzylated by hydrogenolysis catalyzed by palladium on carbon in a solvent such as ethanol The resulting alcohol is treated with p-methoxybenzyl chloπde in the presence of K2C03 in a solvent such as THF to afford
LXV Alcohol LXV can be transformed into ether or sulfide LXVI by the procedures descπbed in METHOD D Deprotection of the p-methoxybenzyl group with TFA in a solvent such as dichloromethane, and subsequent alkylation on oxygen with a suitable reagent such as 4-benzylbenzyl bromide in the presence of K-.CO, in a solvent such as THF affords LXVII
EXPERIMENTAL SECTION
The Examples which follow further illustrate the invention All temperatures set forth in the Examples are in degrees Celsius. All the compounds were characteπzed by proton magnetic resonance spectra taken on a Vanan Gemini 300 spectrometer or equivalent instruments
EXAMPLE 1
2-(2-( 1 -Phenylmethoxycarbonyl-^-phenylmethoxy)ιndolyl)methoxybenzoιc acid
Step 1 2-(5-Phenylmethoxy ιndolyl aldehyde
12.3 g (42 mmol) of ethyl 2-(5-phenylmethoxy)ιndo!yl) carboxylate was dissolved in 100 mL of THF, to which was added 130 mL (130 mmol) of 1 M solution of lithium aluminum hydnde in THF at 0 °C. The reacton was stirred at this temperature for 2 hours and quenched by adding 65 mL of 6 N NaOH solution slowly The product was extracted with ethyl acetate, and the organic phase was washed with aqueous ammonium chloπde Evaporation of the solvent afforded crude alcohol, which without further puπfication was dissolved in 400 mL of THF, 52 g of manganese(IV) oxide was added, and the mixture was stirred at room temperature overnight Removal of manganese oxide by filtration and flash chromatographic punfication using 3 1 hexane ethyl acetate yielded 8 15 g of the title compound Step 2: Benzyl ( l -(2-foπrιyl-5-phenylmethoxy)indolyl)formate
To a solution of 6.9 g (27.5 mmol) of the aldehyde of step 1 in 140 mL of THF was slowly added 61 mL (30.5 mmol) of 0.5 M solution of potassium bis(trimethylsilyl)amide in toluene at
-35 °C. After stirring at this temperature for 10 min, 4.4 L (29.5 mmol) of benzyl chloroformate was added at -35 °C, and the mixture was then warmed from -35 °C to 0 °C for 3.5 hours. The reaction was quenched by pouring into aqueous ammonium chloride. Aqueous work up and flash chromatography using 12: 1 toluene:ethyl acetate afforded 4.8 g of the title compound.
Step 3: Benzyl (l -(2-hvdroxymethyl-5-phenylmethoxy)indolyl)formate
To a solution of 2.9 g (7.5 mmol) of the aldehyde of step 2 in 40 mL of THF and 20 L of trifluoroethanol was added 760 mg (20 mmol) of sodium borohydride at 0 °C.
The mixture was stirred at 0 °C for 30 min and then quenched by adding aqueous ammonium chloride. Flash chromatography using 2: 1 hexane-ethyl acetate afforded 2.2 g of the title compound.
Step 4: Benzyl ( 1 -(2-bromomethyl-5-phenylmethoxy)indolyl)formate
To a solution of 2.2 g (5.7 mmol) of the alcohol of step 3 and 2.05 g (5.0 mmol) of l ,3-bis(diphenylphosphino)propane in 60 mL of dichloromethane was added a solution of 2.0 g (6 mmol) of carbon tetrabromide in 4 mL of dichloromethane at 15 °C. The mixture was stirred at room temperature for 2 hours and 1 g (3 mmol) of 1 ,3- bis(diphenylphosphino)propane was added at room temperature. After 1 hour stirring, the reaction was quenched by adding aqueous ammonium chloride. Aqueous work up and flash chromatography using 4: 1 hexane:ethyl acetate afforded 1.7 g of the title compound.
Step 5: Benzyl (l-(2-(2-formylphenoxy)methyl-5-phenylmethoxy)indolyl)formate
To a solution of 439 mg (3.6 mmol) of methyl 2-hydroxybenzoate in 18 mL of THF was added 6 mL (3 mmol) of 0.5 M solution of potassium bis(trimethylsilyl)amide in toluene at 0 °C. The solution was stirred at 0 °C for 10 min, to which was added a solution of 1 25 g (2 8 mmol) of the bromide, prepared in step 4, in THF at 0 UC The reaction was warmed to room temperature and stirred at this temperature for 2 hours After aqueous work up (NH^Cl / ethyl acetate), the organic solvent was collected, dned over sodium sulfate and evaporated The product was solidified and washed with ethyl acetate. hexane 1 1 Yield 690 mg (51 %)
Step 6
120 mg (0 24 mmol) of the aldehyde of step 5 was dissolved in 1 1 mL of 5' 1.5 THF-acetonιtπle-2,2-dιmethylethanol To this solution was added a solution of 56 mg (0 5 mmol) of sodium chloπte in 0 5 mL water and 1 drop of aqueoues hydrogen peroxide solution After 4 hours, another 56 mg (0 5 mmol) of sodium chloπte was added The mixture was stirred at room temperature for three days Aqueous work up and flash chromatography using 2 5 1 0 05 hexane ethyl acetate-acteic acid afforded 1 10 mg of the title compound.
EXAMPLE 2
4-(2-( 1 -Phenylmethoxycarbonyl-5-phenv!methoxy)ιndolyl)methoxybenzoιc acid
The title compound was prepared according to the procedure descnbed in Example 1 , but using 4-hydroxybenzaldehyde
EXAMPLE 3
3-(2-( 1 -Phenylmethoxycarbonyl-5-phenylmethoxy)ιndolyl)methoxybenzoιc acid
The title compound was prepared according to the procedure descnbed in Example
1 , but using 3-hydroxybenzaldehyde EXAMPLE 4
Benzyl ( l -(2-(2-(1 -oxo-2,2.2-trifluoroethyl)phenoxy)methyl-5- phenylmethoxy)ιndolvπformate
Step 1 : Benzyl ( l -(2-(2-(l -hvdroxy-2.2.2-tnfluoroethyl)phenoxy)methyl-5- phenylmethoχy)ιndolyl)-formate
A solution of 0.4 g (0.8 mmol) of the aldehyde, prepared in step 1 of Example 1 , in 4 mL of THF was cooled to 0 °C. To this were added 0.24 mL ( 1.6 mmol) of tπfluoromethyl tπmethylsilane and 5 mg of tetrabutylammonium fluoride tπhydrate The reaction was stirred for 2.5 hpurs at 0 °C, and additional 0.2 mL (1.3 mmol) of tπfluoromethyl tπmethylsilane and 5 mg of tetrabutylammonium fluonde tπhydrate were added. After stireed at 0 °C for 2 hours, the reaction was worked up with aqueous ammonium chloride and ethyl acetate. Silica gel chromatographic punfication using 4: 1 hexane-ethyl acetate afforded corresponding TMS ether. Treatment of TMS ether with 1.3 mL of IN Hcl solution at room temperature, aqueous woukup using brine and ethyl acetate and chromatographic purification using 3: 1 hexane-ethyl acetate gave 230 mg of the titled compound
Step 2:
To a solution of 150 mg (0.27 mmol) of trifluoroethanol, prepared step 1 , in 5.5 mL of dichloromethane was added 255 mg (0.6 mmol) of the Dess-Martin's peπodinate. The mixture was stirred at room temperature for 1 hour, and then partitioned between aqueous NaHCO, and ethyl acetate. The organic phase was washed once with aqueous NaHC03 and puπfied with chromatography using 3: 1 hexane-ethyl acetate to yield 150 mg of the titled compound. EXAMPLE 5
3-(2-( 1 -Benzy -5-benzyloxy)indolecarboxamιdo)benzoιc acid
Step 1. Ethyl 2-(l -benzyl-5-benzyloχy)ιndolecarboxylate
To a solution of 1 g (3.4 mmol) of ethyl 5-beπzyloxyιndole-2-carboxylate in 12 ml of DMF, sodium hydride (0.163g, 60% oil dispersion, 4.07 mmol) was added at room temperature. The reaction was stmed for 30 minutes. Benzyl bromide (0.44 L, 3.73 mmol) was added at this time and the reaction stined for another hour. On completion of the reaction (monitored by TLC = 0.5 Rf in 3.1 Hexane:Ethyl acetate) it was quenched with water, extracted with ethyl acetate (3X). Organic layers were dried over magnesium sulfate, concentrated and used for the next step
Step 2. 2-(l -Benzyl-5-benzyloxy)ιndolecarboxyιc acid
The ester (3.4 mmol), prepared in step 2, was dissolved in THF (20 mL), methanol (20 mL) and then IN NaOH ( 15 mL) was added The reaction mixture was stirred at room temperature over night at which time it was concenterated, diluted with water, acidified to pH 5 with 10% HCl and extracted with ethyl acetate (3X), the organic extracts were dπed over magnesium sulfate and concentrated to give the indole acid ( 1.14 g, 94.2 %, TLC = 0.5 Rf in 1 : 1 Hexane:Ethyl acetate with 1 % acetic acid)
Step 3 Ethyl 3-(2-( l -benzyl-5-beπzyloxy)ιndolecarboxamιdo)benzoate
The acid (0.54 g, 1.5 mmol) of step 2, l -(3-dιmethylamιnopropyl)-3- ethylcarbodiimide (EDCI) (0.32 g, 1.66 mmol), 4-dιmethylamιnopyπdme (DMAP) (0.018 g, 0.15 mmol) and ethyl 3-amιnobenzoate (0.27 g, 1.66 mmol) were stirred in tetrahydrofuran (9 mL) at room temperature overnight The next day the reaction was diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dπed over magnesium sulfate and concentrated. The crude mateπal was purified on silica gel using 3.1 hexane:ethyl acetate to give pure amide (0.578 g, 76%, TLC = 0.4 Rf in 3: 1 Hexane:Ethyl acetate). Step 4
The ester (0 578 g, 1 15 mmol), prepared in step 3, was dissolved in THF (13 6 L), methanol ( 13 6 mL) and then I N NaOH (9 6 mL) was added The reaction mixture was stirred at room temperature overnight at which time it was concenterated, diluted with water, acidified to pH 5 with 10% HCl and extracted with ethyl acetate (3X), the organic extracts were dned over magnesium sulfate and concentrated to give the titled compound (0 437 g, 80 %, TLC = 0 5 Rf in 3 1 hexane-ethyl acetate with 1 % acetic acid)
The Examples 6. 7. 8. 9. 10 and JJ. in Table I were prepared by the procedures of Example 5 using suitable amines and alkyl halides
EXAMPLE 12
3-(2-(3-(2.4-bιs( 1.1 -dιmethypropyl)phenoxyacetyl)-5-methoxy- 1 -methyl )ιndoly I) methylthιoacetamιdo-4-methoxybenzoιc acid
Step I 2-(5-Methoχy)ιndolylmethanol
Ethyl 5-methoxy-2-ιndolcarboxylate (30 g, 102 mmol) is dissolved in 250 mL of THF and cooled to 0° C and Lithium Aluminum Hydnde (LAH) (255 mL of a 1 0 M solution in THF) is added via addition funnel over 40 minutes The reaction was stirred a further 2 hours at 0° C and then worked up by the addition of 4N NaOH ( 190 mL) The resulting salts are filtered and washed with ethyl acetate (3X400 mL), the filtrates are combined and dned over MgSOj and concentrated to yield 24 8 g of alcohol, which was used for the next reaction directly
Step 2 2-(5-methoxy)ιndolylmethoxy-tert-buthyldιmethylsιlane
The crude indole alcohol prepared in step 1 (6 2 g, 32 6 mmol) was dissolved in DMF ( 10 5 mL) To this solution was added lmidazole (5 5g, 81 5 mmol) and t- butyldimethylsilyl chloπde (5.4g, 35 8 mmol) The mixture was stmed at room temperature overnight. The reaction was poured into water and extracted with ethyl acetate (3X) Organic layers were dned over magnesium sulfate and concentrated. The crude matenal was puπfied on a silica gel column using 19 1 hexane ethyl acetate to give pure product (9.5g, 31 mmol, 94 % yield, TLC. 0.8 Rf in toluene.ethyl acetate 2:1 )
Step 3- 3-(2-tert-butvdιmethylsιlyloxymethyl-5-methoxy)ιndolyl (2,4-bιs(l .l- dιmethypropyl)phenoxy)methyl ketone
2.32 g (7 95 mmol) of 2.4-Bιs-tert-amylphenoxyacetιc acid was dissolved in dichloromethane (21 mL), oxalyl chloπde (1.4 mL 16.1 mmol) was added, followed by dimethyl formamide (0.5 mL) at room temperature. After one hour the reaction is concentrated and azeotroped with toluene and left on the high vacuum for two hours.
In another reaction vessel, a solution of the silyl protected indole, prepared in step 2, (2 g, 6.56 mmol) in ether (20 mL) was added dropwise to ethyl magnesium bromide (2 4 mL of a 3M solution in ether, 7 2 mmol) in ether ( 10 ml), the latter maintained at -78 °C
The reaction was stirred at -60°C for 2 hr. To this reaction solution, the above prepared acid chloπde in ether (4 L) was added slowly. The reaction was maintained between -50°C and -60CC for another 2 hrs. The reaction was then quenched with saturated sodium bicarbonate. Extracted with ethyl acetate (3X) Organic layers were dned over magnesium sulfate and concentrated The crude matenal was punfied on a silica gel column using
19' 1 Hexane:Ethyl acetate to give pure product (2 36 g, 50%, TLC 0.15 Rf in hexane:ethyl acetate 19: 1
Step 4 3-(2-tert-butvdιmethylsιlyloxymethyl-5-methoxy- l -methyl)ιndolyl (2,4-bιs( l , l - dimethvpropyl)phenoxy)methyl ketone
To the ketone ( 1.97g, 3.4 mmol) of in step 3 in 12 mi of DMF, sodium hydnde (0.163g, 60% oil dispersion, 4 07 mmol) was added at room temperature. The reaction was stirred for 30 minutes. Methyl iodide (0.23 mL, 3.73 mmol) was added at this time and the reaction stined for another hour. On completion of the reaction (monitored by TLC) it was quenched with water, extracted with ethyl acetate (3X) Organic layers were dπed over magnesium sulfate, concentrated and the crude product was used for the next step. Step 5: 3-(2-Hvdrσxymethyl-5-methoxy- l -methyl)indolyl (bis-2,4- (1.1.dimethylpropyDphenox v )methyl ketone
A mixture of N-methyl indole, prepared in step 4, (2.01 g, 3.4 mmol) and tetra- butyl ammoniumfluoride (TBAF) (8.5 mL of a 1M solution in THF, 8.5 mmol) in THF
( 17.9 mL) were stined at room temperature for one hour. At this time the reaction was diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using hexane:ethyl acetate 2: 1 to yield pure alcohol (0.82 g, 60 %, TLC: 0.3 Rf in 2: 1 hexaneethyl acetate).
Step 6: Methyl 3-(2-(3-(2.4-bis(l ,l -dimethvpropyl)phenoxy)acetyl-5-methoxy-l - methylindolyl)methylthioacetamido)-4-methoxybenzoate
The indole alcohol, prepared in step 5, (0.20 g, 0.43 mmol) was dissolved in dichloromethane (0.7 mL) and treated with tnethylamine (0.1 mL, 0.64 mmol) and cooled to 0° C at which time mesyl chloride (0.04 mL 0.52 mmol) was added over 5 minutes, followed by addition of two drops of DMF. T e reaction was stined for a further 2 hour at 0°C, it was then concentrated and used directly for the next reaction. The above prepared mesylate was dissolved in DMF (0.8 mL). The solution was degassed by bubbling nitrogen through for ten min. Cesium carbonate (0.25 g, 1.29 mmol) was added and then thiol (0.1 1 g, 0.43 mmol), prepared in Intermediate 1 , was added. The mixture was stirred overnight, then poured into saturated ammonium chloride and extracted with ethyl acetate (3X), dried, concentrated. The crude material was purified on a silica gel column using hexane:ethyl = 2: 1 acetate to give pure product (0.12 g, 40%, TLC: 0.3 Rf in hexane:ethyl acetate 1 : 1 ).
Step 7:
The ester, prepared in step 6, (0.12 g, 0.17 mmol) was dissolved in THF ( 1.0 mL), methanol (1.0 L) and then IN NaOH (0.4 mL) was added. The reaction mixture was stirred at room temperature overnight at which time it was concenterated, diluted with water, acidified to pH 5 with 10% HCl and extracted with ethyl acetate (3X), the organic extracts were dπed over magnesium sulfate and concentrated to give the titled compound (85 mg, 72 %, TLC = 0.3 Rf in 1.1 Hexane Ethyl acetate with 1 % acetic acid)
EXAMPLES 13. 14. 15 and 16 in Table I were prepared by the procedures of Example 12 using Ethyl 2-(5-benzyloxy)ιndolecarboxylate, acetyl chloπdes and suitable alkyl halides
EXAMPLE 17
3-(2-(-5-benzyloxy-l -(2.4-bιs( 1.1 -dιmethv)propyπphenoxyacetvPιndolιnyl) methylthioacetamidobenzoic acid
Step I 2-(5-Benzyloxy)ιndolιnylmethanol Ethyl 5-benzyloxy-2-ιndolecarboxylate (30 g, 102 mmol) was dissolved in 250 mL of
THF and cooled to 0° C, to which Lithium Aluminum Hydnde (LAH) (255 mL of a 1.0 M solution in THF) was added via addition funnel over 40 minutes The reaction was stmed a for 2 hours at 0 °C and then worked up by the addition of 4N NaOH ( 190 mL). The resulting salts were filtered and washed with ethyl acetate (3X400 mL), the filtrates were combined, dried over MgS0 and concentrated to yield 24.8 g. This crude matenal was then dissolved in glacial acetic acid (260 mL) and the resulting yellow solution was cooled to 15° C, sodium cyanoborohydride (18.5 g, 294 mmol) was added portionwise over 10 minutes, and the resulting mixture was stmed for 3 hours The reaction was quenched by pouπng slowly into 1.5 liters of nearly saturated NaHCO,, extracted with ethyl acetate (3X), dπed over MgS04 and concentrated to yield a orange solid (29.6 g).
Step 2 tert-Butyl l-(5-benzyloxy-2-hvdroxymethv)lιndolιnylformate
25 g (85 mmol) of crude alcohol, prepared in step 1 , and 4-dιmethylamιno pyπdine (DMAP) ( 1.19 g, 9.78 mmol) were dissolved in dichloromethane ( 180 mL). The solution was cooled to 0C C and then tnethylamine ( 13.6 mL, 98 mmol) was added to it. After 10 minutes of stirπng a solution of di-tert-butyl dicarbonate (21.3 mL, 98mmol) dissolved in dichloromethane (20 mL) was added via synnge pump over 2 hours After 1 hour of stirnng the reaction was quenched by the addition of 1/2 saturated NH4C1 solution and extracted with CH-C1, (3X), dned over MgS0 and concentrated to yield 36 3 g of a yellow oil, which was punfied by column chromatography using a hexane:ethyl acetate gradient of 9- 1 to 4 1 to 1 1 to deliver the product ( 15 25 g, 44%)
Step 3 Ethyl 2-(5-benzyloxy-l -tert-butoxycarbonyl)ιndolιnylmethylthιoacetate
The carbamate, prepared in step 2, ( 15.25 g, 43 mmol) was dissolved in dichloromethane (180 mL) and treated with tnethylamine (9.0 mL, 64 4 mmol). The solution was cooled to -10° C at which time mesyl chlonde (4.3 mL. 56 mmol) was added over 5 minutes The reaction was stined for a further 2 hour at -10 °C, it was then concentrated and used directly for the next displacement reaction
The above prepared mesyiate was dissolved in DMF (85 mL, degassing the solvent is strongly reccomended) cesium carbonate (35 g, 107 3 mmol) was added and then ethyl thioacetate (4 70 mL, 42 9 mmol) was added The mixture was stined for 1 day, then poured into 1/2 sturated ammonium chlonde and extracted with ethyl acetate (3X), dned, concentrated and chromatographed (hexane. ethyl acetate gradient 10: 1 to 4 1 ) to yield 8.55 g of a yellow oily product.
Step 4 2-(5-Benzyloxy-l -tert-butoxycarbonyl)ιndolιnylmethylthιoacetιc acid
To a solution of the indoline ester, prepared in step 3, (5g, 1 1 mmol) in IM potassium hydroxide in methanol (100 mL), water (10 mL) was added. The reaction was stmed at room temperature for two hours at which time it was diluted with water, acidified to pH 5 with 10% HCl and extracted with ethyl acetate (3X), the organic extracts were dπed over magnesium sulfate and concentrated to give the indoline acid ( 4.5g, 95.5%, TLC =
0.5 Rf in 2.1 hexane:ethyl acetate with 1 % acetic acid). The crude matenal was used for the next step directly
Step 5 Ethyl 3-(2-(5-benzyloxy- l-tert- butoxycarbonvDindolinvDmethylthioacetamidobenzoate
The acid (3g, 7 mmol), prepared in step 4, l-(3-dιmethylamιnopropyl)-3- ethylcarbodπmide (1.6g, 8.4 mmol), 4-dιmethylamιnopyπdιne (0.85g, 7 mmol) and ethyl 3-amιnobenzoate ( 1.27 g, 7.7 mmol) were stmed in tetrahydrofuran (43 mL) at room temperature overnight. On next day the reaction was diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using 3: 1 hexane:ethyl acetate to give the product (3.4g, 85%, TLC = 0.3 Rf in 3: 1 hexane:ethyl acetate).
Step 6: Ethyl 3-(2-(5-benzyloxy)indolinyl)methylthioacetamidobenzoate
To the indoline (3.4g, 5.9 mmol) of step 5, trifluoroacetic acid (24 mL) was added and the reaction stined for 1 hour at 0°C. The reaction was quenched by the addition of water and the TFA neutralized by the addition of sodium bicarbonate, the aqueous layer was extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using 2: 1 hexane:ethyl acetate to yield product (2.7 g, 96 %, TLC = 0.3 Rf in 2: 1 hexane:ethyl acetate).
Step 7: Ethyl 3-f 2-f 5-benzyloxy- 1 -(2.4-bis( 1.1 - dimethyl)propyl)phenoxyacetyl)indolinvπ methylthioacetamidobenzoate
The 2,4-bis( l , l -dimethylpropyl)phenoxyacetic acid (0.228 g, 0.78 mmol) was dissolved in dichloromethane (2 mL), to which oxalyl chloride (0.14 mL 1.6 mmol) was added followed by dimethyl formamide (0.1 mL) at room temperature. After one hour the reaction is concentrated and azeotroped with toluene and left on the high vacuum for two hours. The indoline ester (0.308 g, 0.65 mmol), prepared in step 6, and 4- dimethylaminopyridine (0.008 g, 0.066 mmol) were dissolved in dichloromethane ( 1.2 mL) and then the above prepared acid chloride in dichloromethane (0.5mL) was added followed by the addition of tnethylamine (0.28mL, 1.95 mmol). The reaction was stined at room temperature overnight, and then diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using 2: 1 hexane:ethyl acetate to yield product (0.291 g, 60 %, TLC = 0.4 Rf in 2: 1 hexane:ethyl acetate).
Step 8:
The ester (0.231 g, 0.31 mmol) of step 7 was dissolved in THF (4.3 mL), methanol (4.3 L) and than IN NaOH (3.2 mL) was added. The reaction mixture was stined at room temperature overnight at which time it was concenterated, diluted with water, acidified to pH 5 with 10% HCl and extracted with ethyl acetate (3X), the organic extracts were dπed over magnesium sulfate and concentrated to give the titled product ( 0 207 g, 93 2 %, TLC = 0 3 Rf in 2 1 hexane ethyl acetate with 1 5 % acetic acid)
EXAMPLE 18
3-(2-(-5-Benzyloxy-l -(2.4-bιs( l .l -dιmethv)propyl)phenoxyacetyl)ιndolιnvD methylthιoacetamιdo-4-methylbenzoιc acid
Step 1 Ethyl 2-(5-benzyloxy)ιndolιnylmethylthιoacetate
The N-tert-butoxycarbonyl indoline (3 0 g, 6 6 mmol), prepared in step 3 of Example 17, was added to a flask and cooled to 0 °C To this reaction mixture tπfluoroacetic acid was added (35 mL) and the reaction was stired for 1 hour at 0 °C and then 1 hour at rt The reaction was quenched by the addition of water, and the TFA was neutralized by the addition of solid sodium bicarbonate, the aqueous layer was extracted with ethyl acetate (4X) and dned over magnesium sulfate and concentrated to an orange oil (1.85 g, 79%) that was used directly for the next step
Step 2 Ethyl 2-(5-benzyloxy-l -(2.4-bιs(l , l -dιmethv)ρropyl)phenoxyacetyl)- indolinylmethylthioacetate
2,4-Bιs( 1 , 1 -dιmethy)propy Ophenoxyacetic acid (2 Og, 6 8 mmol), dichloromethane
(15 mL), oxalyl chlonde (1 2 mL, 13 6 mmol), dimethylformamide (0 1 mL) were stmed at 0° C for 45 minutes at which time the reaction is concentrated and azeotroped with toluene (I X) and concentrated on the high vac for 2 hours before use The indoline ester (1 85g, 5.2 mmol), prepared in stepl , and 4-dιmethylammopyπdιne (008 g) were dissolved in dichloromethane ( 15 mL) and then the above generated acid chloπde in dichloromethane (5 mL) was added followed by the addition of tnethylamine (0 95 mL, 6 8 mmol) The reaction was stmed 16 hours at rt, worked up and concentrated (4 0 g, orange oil), chromatographed using a 9 1 to 6 1 gradient of hexaneethyl acetate to yield the product (2.5g, 75%) that was used for the next step without further puπfication Step 2-(5-Benzyloxy- 1 -f 2.4-bιsf 1.1 - dιmethv)propyl)phenoxyacetyl)ιndolιnylmethylthιoacetιc acid
The ester (2 5 g, 3 9 mmol), prepared in step 2, was dissolved in THF (20 mL), methanol (6 mL) and then 1 N sodium hydroxide ( 12 mL) was added The resulting mixture was stmed 24 hours at which time it was concentrated, diluted with water, acidified to pH 4 with concentrated HCl and extracted with ethyl acetate (4X), the organic extracts were dπed over magnesium sulfate, concentrated, and punfied via chromatography (3 1 hexane ethyl acetate with 1 % acetic acid) to yield 1 17 g ( 50%) of the product as white solid
Step 4 Methyl 3-(2-(5-benzyloxy- l -(2,4-bιs( 1.1- dιmethv)propyl)phenoxyacetvhιndolιnyl) methylthιoacetamιdo-4-methylbenzoate
The acid (0 20 g, 0.33 mmol), prepared in step 3, EDCI (0 08 g, 0 43 mmol),
DMAP (4 mg, 0 03 mmol) and methyl 3-amιno-4-hydroxy benzoate (0 06 g, 0 33 mmol) were dissolved in THF (3 mL) and refluxedlό hours Aqueous workup with ammonium chloπde and ethyl acetate and puπfication via silica gel chromatography (hexane ethyl acetate 3 1 ) yielded 0 13 g (52%) of the product as a white solid
Step 5
The titled compound was prepared from ester, prepared in step 4, according to the procedure descπbed in step
EXAMPLES 17 to 36 in Table 2 were prepared according to the procedurs descπbed in either Example 17 or Example 18 EXAMPLE 37
2-(5-Benzyloxy-l -(3.5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methylthioacetic acid
Step 1 : 2-(5-Benzyloxy- 1 -(3.5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methanol
A 1 -L oven-dried round bottom flask fitted with a magnetic stirring bar and equalizing dropping funnel was charged with 17.0 g ( 59 mmol) of 3,5- bis(trifluoromethyl)phenoxyacetic aci, DMF (5 drops) and anhydrous CH2C12 (300 mL). Oxalyl chloride (23 mL, 263 mmol) was added dropwise over 10 min. After stirring for 2.5 h at room temperature solvent, excess oxalyl chloride were removed in vacuo to afford acid chloride as a white solid. This was used immediately in the next reaction.
A 1 -L oven-dried round bottom flask fitted with a magnetic stirring bar and equalizing dropping funnel was charged with 1 .3 g (60 mmol) of 2-(5- Benzyloxy)indolinylmethanol, prepared in stepl of Example 17, DMAP (0.73 g, 6 mmol) and anhydrous CH,CI2 (300 L). After cooling to 0 °C, a solution of above prepared acid chloride (59 mmol) in anhydrous CH2C12 (100 mL) was added dropwise, followed by NEt3 (9 mL, 64.7 mmol). After stirring for 1 h at 0 °C the reaction mixture was washed with saturated NaHC03 solution (100 mL), 1 N HCl solution (100 mL) and H,0 (100 mL), dried over Na,S04 and filtered. The solvent was removed in vacuo. Purification by column chromatography in silica gel using 25-40% AcOEt in hexane afforded product as a light yellow solid. Yield 22.0 g (71 %).
Step 2: Ethyl 2-(5-benzyloxy-l -(3.5-bis(trifluoromethyl)phenoxyacetyl)indolinyl) methylthioacetate
A 500-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with alcohol (19.0 g, 36.15 mmol), prepared in step 1 , anhydrous CH,CI2 (300 mL), and NEt3 (7.5 mL, 54.23 mmol). MsCl was added dropwise over 2 min and the reaction mixture was stined at room temperature for 10 min. The solution was diluted with CH,Cl2 (500 mL) and washed with IN HCl solution ( 100 L) and saturated NaHC03 solution ( 100 mL). The CH2C1, solution was dried over Na2S04 and filtered. The solvent was removed and the mesylate was used in the next step without further purification. A 500-mL oven-dπed round bottom flask fitted with a magnetic stimng bar was charged with ethyl thioacetate (4 2 mL, 38 5 mmol), and anhydrous THF (75 mL) After cooling in a dry ice/acetone bath NaN(SιMe3)2 (1 M solution in THF, 50 mL, 50 mmol) was added After 15 min a solution of above prepared mesylate (21 g, 35 mmol) in anhydrous THF (60 mL) was added After 15 min the reaction mixture was allowed to warm to room temperature After stimng at room temperature for 100 min the reaction was heated at reflux for 4 h The solution was allowed to cool to room temperature It was diluted with CHC13 (500 mL), washed with saturated Na,C03 solution (200 mL) and IN HCl solution (200 mL) The organic solution was dned over Na2S04 and filtered The solvent was removed in vacuo The crude matenal was punfied by column chromatography on silica gel using 15% AcOEt in hexane to afford 13 8 g (63%) of product
Step 3
A 250-mL round bottom flask fitted with a magnetic stimng bar was charged with ester ( 12 45 g, 19 8 mmol), prepared in step 2, THF (100 mL), MeOH (33 mL) and H20 (33 mL). LiOH H20 ( 1.08 g, 25 7 mmol) was added and the reaction mixture was stmed at room temperature for 3 h. The solvents were removed in vacuo The residue was taken into IN HCl solution (200 mL) and extracted with AcOEt (2 x 400 mL) The combined extracts were washed with 1 N HCl solution ( 100 mL), dned over Na,S04 and filtered The solvent was removed in vacuo to afford the titled compound Yield 1 1 9 g ( 100%)
EXAMPLE 38
-f2-(-5-Benzyloxy-l -(3.5- bιs(tnfluoromethyl)phenoxyacetyl)ιndolιnyl)methylthιoacetamιdo) benzene- 1.3- dicarboxylic acid
Step 1 5-(2-(-5-Benzyloxy- 1 -(3.5-bιs(tnfluoromethyl)phenoxyacetyl)ιndolιnyl) methylthιoacetamιdo)benzene- 1.3-dιcarboxylate
A 100-mL oven-dπed round bottom flask fitted with a magnetic stimng bar was charged with acid (1 2 g, 2 mmol), prepared in step 3 of Example 37, anhydrous THF (40 mL), EDCI (0 544 g, 2 8 mmol), DMAP (0 024 g, 0 2 mmol), and 5-amιno- 1 ,3- benzenedicarboxyiic acid (0 46 g, 2 2 ml) The reaction mixture was heated at reflux until no change was detected by TLC The solvent was removed in vacuo The residue was dissolved in CH (200 L), washed with 1 N HCl solution (25 mL), dπed over Na2S04 and filtered The solvent was removed in vacuo The crude matenal was puπfied by column chromatography on silica gel using 1 -2% MeOH in CH,C12 to afford I 2 g (77%) of product
Step 2
A 25-mL round bottom flask fitted with a magnetic stirπng bar was charged with ester (0 6 g, 0 76 mmol), prepared in stepl , THF (7 5 mL), MeOH (2 5 mL) and H20 (2 5 mL) LiOH H20 (0084 g, 2 mmol) was added, and the reaction mixture was st ed at room temperature for 6 h The solvents were removed in vacuo The residue was taken into IN HCl solution (10 mL) and extracted with AcOEt (2 x 50 mL) The combined extracts were dπed over Na2SO4 and filtered and removed in vacuo The crude matenal was puπfied by column chromatography on silica gel (eluant 5% MeOH in CHCB + 0 5- 0 7% AcOH) to yield 0 28 g (46%) of the titled compound
EXAMPLES 39. 40. 43 in Table 3 were prepared according to the procedurs descπbed in either Example 38 EXAMPLE 41
5-(2-(-5-Benzyloxy-l -(3.5- bιs(tnfluoromethyl)phenoxyacetyl)ιndolιnyl)methylthιoacetamιdo)-3- hvdroxymethylbenzoic acid
Step 1 Methyl 5-(2-(-5-ben7yloxy-l -(3.5-bιs(tnfluoromethyl)phenoxyacetyl)ιndolιnyl) methylthιoacetamιdo)-3-tert-butyldιmethylsιlyloxymethylbenzoate
This compound was prepared according to the procedure descπbed in step 1 of Example 38
Step 2 Methyl 5-(2-(-5-benzyloχy- l -(3.5-bιs(trifluoromethyl)phenoxyacetyl)ιndolιnyl) methylthioacetamidoVl-hvdroxymethylbenzoate
A 25-mL oven-dπed round bottom flask fitted with a magnetic stirnng bar was charged with silyl propected ester (1.32 g, 1 5 mmol), prepared in step 1 , anhydrous THF ( 10 mL), and TBAF ( 1 M solution in THF, 2.5 mol equiv ) The reaction mixture was stined at room temperature for 3 hours The solvent was removed in vacuo The oily residue was puπfied by column chromatography on silica gel using 0-30% AcOEt in CH2C12 to afford 0 94 g (92%) of desired product
Step 3
The titled compound was prepared according to the procedure descπbed in step 2 of Example 38
EXAMPLE 42 in table 3 was prepared according to the procedures descπbed in Example 41 EXAMPLE 44
5-(2-(-5-Hvdroxy- l -(3.5- bis(trifluoromethyl)phenoxyacetvDindolinyl)methylthioacetamido) benzene- 1.3- dicarboxylic acid
Step 1 : 2-(5-Hvdroxy- 1 -(3,5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methanol
A 500-mL Pan Hydrogenation bottle was charged with 2-(5-Benzyloxy-l-(3,5- bis(trifluoromethyl)phenoxyacetyl)indolinyl)methanol (10 g, 19.1 mmol), prepared in step 1 of Example 37, 5% Pd on carbon ( 1.0 g), AcOEt ( 150 L) and MeOH ( 100 mL) and subsequently hydrogenated at 50 psi for 18 h. The reaction mixture was filtered through Celite and concentrated in vacuo to afford crude product. This was used in the next step reaction without further purification.
Step 2: 2-(5-(4-Methoxy)benzyloxy-l -(3.5- bis(trifluoromethyl)phenoxyacetvπindolinyl)methanol
A 1-L oven-dried round bottom flask fitted with a magnetic stirring bar and reflux condenser was charged with alcohol (8.56 g, 19.7 mmol), prepared in stepl , 200 mesh K,C03 (6.53 g, 47.2 mmol), KI (3.91 g, 23.6 mmol) and finally the p-methoxy benzyl chloride (3.2 mL, 23.6 mmol) in 450 mL of anhydrous acetonitrile. The reaction mixture was heated at reflux for 4 h. The reaction mixture was partitioned between AcOEt (500 mL) and H20 (200 mL). The aqueous layer was extracted with AcOEt (3 x 500 mL). The combined AcOEt extracts were washed with brine (500 mL), dried over Na2S0 and filtered. The solvents were removed in vacuo. Purification of the residue by column chromatography on silica gel (eluant: 40% AcOEt in hexane) afforded desired product. Yield 8.7 g (83%).
Step 3: Methyl 5-(2-(-5-(4-methoxy)benzyloxy- l -(3.5-bis(trifluoromethyl)phenoxyacetyl) indolinyl)methylthioacetamido)benzene- 1.3-dicarboxylate
A 100-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with alcohol (3.2 g, 5.77 mmol), prepared in step 2, and anhydrous CH2C (44 mL) The reaction mixture was cooled to 0"C and added anhydrous Et,N (1 2 mL. 8 61 mmol) followed by MsCl (0.53 mL, 6 84 mmol) The reaction mixture was stined at 0 °C for 5 min. The reaction mixture was partitioned between CH,C12 (100 mL) and H,0 (50 mL) The aqueous layer was extracted with CH2C12 (3 x 100 mL). The combined CH,CI2 extracts were washed with 1 N HCl solution ( 100 mL), saturated NaHCO, solution ( 100 mL), H20 ( 100 mL), bπne ( 100 mL), dπed over Na,S0 and filtered. The solvents were removed in vacuo to afford mesylate This was used in the next step reaction without further punfication.
A 100-mL oven-dned round bottom flask fitted with a magnetic stimng bar and reflux condenser was charged with above prepared mesylate (3 60 g, 5 70 mmol), anhydrous Cs,C03 (5 19 g, 15 9 mmol) and anhydrous DMF (20 mL) The reaction solution was passed through N2 for 15 mm. Methyl 5-thιoacetamιdo-l ,3- benzenedicarboxylate, prepared in Intermediate 2, was added in one portion and the reaction mixture was heated at 50 °C for 18 h The reaction mixture was partitioned between AcOEt (500 mL) and H20 (200 mL) The aqueous layer was extracted with
AcOEt (3 x 100 mL) The combined AcOEt extracts were washed with saturated Na,C03 solution (100 mL), H,0 (100 mL), bπne (500 mL), dned over Na2S04 and filtered. The solvents were removed in vacuo Punfication of the residue by column chromatography on silica gel (eluant. 5% AcOEt in CH,C12 ) afforded product Yield 2 5 g (53%)
Step 4- Methyl 5-(2-(-5-Hvdroxy-l -(3.5-bιs(trifluoromethyl)phenoxyacetyl) ιndolιnyl)methylthιoacetamιdo)benzene- 1 ,3-dιcarboxylate
A 100-mL oven-dned round bottom flask fitted with a magnetic stimng bar was charged with ester (2.60 g, 3.17 mmol), prepared in step 3, and anhydrous CH2C12 (30 mL)
To the reaction mixture was added TFA (25 mL) in several portions over 1 m The reaction mixture was poured onto 500 L saturated NaHCO, solution and extracted with CH2CL (3 x 100 mL) The combined CH2C12 extracts were washed with saturated Na2C03 solution (200 mL), H20 (200 mL), bπne (500 mL), dπed over Na,S0 and filtered The solvents were removed in vacuo. Punfication of the residue by column chromatography on silica gel (eluant 12.5% - 20% AcOEt CH2C12 ) afforded the product Yield 1.5 g (68%) Step 5
A 25-mL round bottom flask fitted with a magnetic stirnng bar was charged with ester (270 mg, 0 40 mmol), prepared in step 4, LiOH hydrate (3 3 equiv ), THF (3.6 mL), MeOH ( 1.2 mL) and H20 ( 1.2 mL). The reaction mixture was heterogeneous with white solid suspended in the solution After stimng for 4 h, more solvents were added in 3 1 : 1 = THF ' MeOH . H20 to make a clear solution The reaction mixture was stirred at room temperature for 18 h and monitored by TLC. The reaction mixture was acidified with 1 N HCl solution to pH = 2 or with acetic acid to pH = 4 and then partitioned between AcOEt (20 mL) and H20 (20 mL) The aqueous layer was extracted with AcOEt (3 x 20 mL)
The combined AcOEt extracts were washed with H,0 (20 mL), bnne (20 mL), dπed over Na,S04 and filtered. The solvents were removed in vacuo Punfication of the residue by column chromatography on silica gel followed by recrystallization from acetone / hexane afforded 130 mg of the titled compound (50%)
EXAMPLE 45
5-(2-(5-(3.5-Dιbromo)benzyloxy- l -(3.5-bιs(tπfluoromethyl)phenoxyacetyl)indolιnyl) methylthιoacetamιdo)benzene- 1 ,3-dicarboxyiιc acid
Stepl Methyl 5-(2-(5-(3.5-Dιbromo)benzyloxy- l-(3.5- bιs(tπfluoromethyl)phenoxyacetyl) ιndolιnvPmethylthιoacetamιdo)benzene-l ,3- dicarboxylate
A 25-mL oven-dned round bottom flask fitted with a magnetic stimng bar and reflux condenser was charged with methyl 5-(2-(-5-Hydroxy- l -(3,5- bιs(tπfluoromethyl)phenoxyacetyl) ιndo!ιnyl)methylthιoacetamιdo)benzene- 1 ,3- dicarboxylate (0.19 g, 0.27 mmol), prepared in step 4 of Example 4. 200 mesh K2CO, (2.4 equiv ) and 3,5-dιbromobenzyl bromide (1 2 equiv.) in 7.5 mL of anhydrous acetonitnle. The reaction mixture was heated at 70 °C for 2 h. The reaction mixture was partitioned between AcOEt (30 mL) and H20 (20 mL) The aqueous layer was extracted with AcOEt (3 x 30 mL). The combined AcOEt extracts were washed with bπne (50 mL), dπed over Na2S0 and filtered. The solvents were removed in vacuo. Punfication of the residue by column chromatography on silica gel using 15% EtOAc in dichloromethane afforded 0 20 g of the product (77%)
Step 2
The titled compound was prepared from the ester, prepared in step 1 , according to the procedure descπbed in step 5 of Example 44
EXAMPLES 46 to 50 in table 4 were prepared according to the procedures descnbed in
Example 44, but using conesponding alkylating reagent
EXAMPLE 51
Methyl l-(2-(5-benzyloxy-l -(4-benzylbenzovPιndolιnvPmethylthιoacetamιdo)benzoate
4-Benzylbenzoιc acid (0 19g, 0 91 mmol) was dissolved in dichloromethane (2 3 ml), next oxalyl chloπde (0 16 mL, 1.82 mmol) was added followed by dimethylformamide (0 5 mL) at room temperature. After one hour the reaction was concentrated and azeotroped with toluene and left on high vaccum for two hours
Ethyl 3-(2-(5-benzyloxy)ιndolιnyl)methylthιoacetamιdobenzoate (0 308 g, 0 65 mmol), prepared in step 6 of Examle 17, and 4-dιmethylamιnopyπdιne (8 mg, 0 066 mmol) were dissolved in dichloromethane (1 2 mL) and then the above prepared acid chloπde in dichloromethane (0 5 mL) was added followed by the addition of tnethylamine
(0.28 mL, 1 95 mmol) The reaction was stined at room temperature overnight The reaction was diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dπed over magnesium sulfate and concentrated The crude material was puπfied on silica gel using 2 1 hexane:ethyl acetate to yield 0 354 g of the titled product (81 7%, TLC = 04 Rf in 2.1 hexaneethyl acetate) EXAMPLE 52
3-(2-(5-Benzyloxy- 1 -(4-beπzylbenzovPindolinvPmethylthioacetamido)benzoic acid
The ester (0.354 g, 0.53 mmol), prepared in Example 51 , was dissolved in THF
(5.6 mL), methanol (5.6 L) and than IN NaOH (4.2 mL) was added. The reaction mixture was stined at room temperature overnight at which time it was concentrated, diluted with water, acidified to pH 5 withl 0% HCl and extracted with ethyl acetate (3X). The organic extracts were dried over magnesium sulfate and concentrated to give the titled product (0.32 g, 94.4 %, TLC = 0.3 Rf in 2: l hexane:ethyl acetate with 1.5 % acetic acid).
EXAMPLES 53 to 58 in Table 5 were prepared according to the procedures described in Example 51 and 52.
EXAMPLE 59
3-(2-(5-Benzyloxy-l -(2-naphthoxyacetvPindolinvPmethylthioacetamido)-4- methoxybenzoic acid
Step 1 : Methyl 3-(2-(5-benzyloxyindolinvPmethylthioacetamido)-4-methoxybenzoate
This compound was prepared according to the procedures described in step 6 of Example 17. but with methyl 4-methoxybenzoate.
Step 2: Methyl 3-(2-(5-benzyloxy-l -(2-naphthoxyacetvPindolinvPmethylthioacetarnido)- 4-methoxybenzoate
The indole ester (0.22 g, 0.45 mmol), prepared in step 1 , 2-naphthoxyacetic acid
(0.1 1 g, 0.53 mmol), EDCI (0.10 g, 0.53 mmol) and DMAP (5 mg, 0.04 mmol) were weighed into a flask that was equipped with a condenser, flushed with nitrogen, and then tetrahydrofuran (5 mL) was added and the reaction was brought to reflux for 18 hours; the reaction was diluted with 1/2 saturated ammonium chloride and ethyl acetate, extracted 3X with ethyl acetate, dried over magnesium sulfate, concentrated to yield (0 30 g, 100% crude) a white solid that was used without purification
Step 3
The ester ( 0 12 g, 0.20 mmol), prepared in step 2, was dissolved in THF7 methanol and then I N sodium hydroxide (0 8 mL) was added and the resulting mixture was stmed 16 hours at RT and a further 5 hours at 45°C, workup yielded 0.12 g of a yellow solid that was puπfied via preparative TLC ( 1 1 hexane ethyl acetate with 1 % acetic acid) to yield 0 12 g of the titled product (95%)
EXAMPLES 60 to 63 in Table 5 were prepared according to the procedures descπbed either in Example 59 or in Examples 51 and 52
EXAMPLE 64
3-(2-(5-benzyloχy-l -tert-butoxycarbonvPιndolιnvPmethylsulfonylacetamιdobenzoιc acid
Step 1 Ethyl 3-(2-(5-benzyloxy- l -tert-butoxycarbonyl)ιndolιnyl)methylsulfonyl acetamidobenzoate
To a solution of Ethyl 3-(2-(5-benzy loxy- 1 -tert-butoxycarbonyl)ιndolιnyl)methy Ithioacetamidobenzoate (0 05g, 0 09 mmol), prepared in step 5 of Example 17, in dichloromethane (0 1 mL) at room temperature, m-chloroperbenzoic acid (0.06g of 60% m-cPBA, 0.21 mmol) was added and the reaction stmed overnight Next day the reactton was quenched with an aqueous solution of sodium bicarbonate, extracted with eth l acetate (3X), dπed over magnesium sulfate and concentrated The crude sulfone (0.52g, 98%, TLC = 0.3 Rf in 1 1 hexane:ethyl acetate) was used for the next reaction directly Step 2.
The titled compound was prepared according to the procedure descπbed in step 3 of Example 59
EXAMPLES 66 and 65 were prepared according to the procedures descπbed in Example 18.
EXAMPLE 67
2-(2-(-5-Benzyloxy- 1 -( 2.4-bιsf 1.1 - dιmethv)propyPphenoxyacetvPιndolιnvPmethylthιoben7θic acid
Step 1 • 5-Benzyloxy- 1 -(2.4-bιs( 1 , 1 -dιmethv)propy PphenoxyacetvP-2- hvdroxymethylindohne
The dnsopropylethylamine (3.5 mL, 20.5 mmol), DMAP(0 25 g, 2.05 mmol) and the indoline alcohol (4.53 g, 17 7 mmol), prepared in step 1 of Example 17, were weighed into a flask which was flushed with nitrogen and cooled to 0° C at which time a 0° C solution of di-tert-amylphenoxyacetyl chlonde (20.5 mmol) in CH,C1, (50 mL) was added via cannula. The resulting solution was left to warm to room temperature overnight and then quenched by the addition of 1/2 saturated ammonium chloride and CH2C12, the solution was extracted with CH2CI2 (3X), the combined layers were dπed over magnesium sulfate and concentrated to yield ( 10.4 g) of a yellow foam that was punfied via chromatography using a gradient (hexanexthyl acetate 7: 1 to 3: 1 to 1 : 1 ) to yield 3.62 g of the product.
Step 2 2-(5-Benzyloxy- 1 -(2.4-bιs( 1.1 -dιmethv)propyPphenoxyacetvPιndolιnylmethyl methylsulfonate
To a solution of alcohol ( 1.2 g, 2.26 mmol) in CH,C12 ( 15 mL), prepared in step 1 , is added tnethylamine (0.44 mL, 3.16 mmol). The solution is brought to -50 °C and then mesyl chloπde (0.23 mL, 2 93 mmol) is added The mixture is stmed 2 h at -50 °C, quenched with saturated ammonium chloride and allowed to come to rt The mixture is taken up in CHCl, (50 mL), washed with saturated sodium bicarbonate ( 1 X 10 mL), bπne ( 1 X 10 mL), dπed (MgS04), filtered and concentrated to afford the product ( 1 19 g, 86%)
Step 3 Methyl 2-(2-(-5-benzyloxy- l-(2.4-bιs( l . l -dιmethv)propyl)phenoxyacetvP indolinvPmethylthiobenzoate
To a solution of mesylate (0 54 g, 0.89 mmol), prepared in step 2, in degassed DMF (2 mL) is added CsCO, (0 724 g, 2.22 mmol) and methyl thiosahcylate (0.134 mL,
0 98 mmol) The mixture is stmed 4 h, taken up in ethyl acetate (20 mL), washed with bnne (3 X 3 mL), dried (MgS0 ), filtered and concentrated Chromatography (gradient, hexane:ethyl acetate 15.1 to 4 I ) afforded 0.53 (86%) of the title compound as a yellow oil
Step 4
The titled compound was prepared according to the procedure descπbed in step 3 of Example 59.
EXAMPLE 68 was prepared according to the procedures descπbed in Example 67
EXAMPLE 69
3-(N-(2-(-5-Benzyloxy- l-(2.4-bιs( l .l -dιmethv)propyPphenoxyacetyl)ιndolιnvP rnethylthioethvPaminobenzoic acid
The titled product was prepared according to the procedures described in step 3 of Example 59, but using Intermediate 15. EXAMPLE 70
3-N-Methyl-(2-(-5-Benzyloxy- 1 -(2.4-bιs( 1.1 -dιmethv)propyPphenoxyacetyl)ιndolinyl) methylthιoacetamιdo-4-methoxybenzoιc acid
An oven-dned 100 mL, 3-neck round bottom flask, equipped with a stir bar and nitrogen inlet, was charged with methyl 3-(2-(-5-Benzyloxy-l -(2,4-bιs(l ,l- dιmethy)propyl)-phenoxyacetyl)ιndoiιnyl)methylthιoacetamido-4-methoxybenzate (581 mg, 0.757 mmol), prepared in the synthesis of Example 20 using the procedures descnbed in Example 18, and 10 mL of THF was added via synnge To the resulting yelllow solution was added NaH (60% suspension in mineral oil, 39 mg, 0.975 mmol). The reaction mixture was st ed at 25 °C for 1 5 h to afford a pale suspension. Methyl iodide ( 161 mg, 1.14 mmol) was added, and the reaction mixture was stined at 25 °C for 2 days. After chilling to 0 °C, water was added ( 10 mL), followed by 50 L of half saturated ammonium chlonde, and 100 mL of EtOAc. The layers were separated, and the aqueous phase was extracted once with EtOAc (50 mL). The combined organic phases were dπed (sodium sulfate), filtered, and concentrated to afford 0 6 g of crude product as an orange oil. This material was dissolved in 15 mL of THF and 10 mL of methanol, and 7 mL of 1 N NaOH solution was added, under nitrogen. After being stmed for 2 h at 25 °C, the reaction mixture was concentrated to dryness on the rotary, and 100 mL of IN HCl, and 100 mL of
EtOAc were added. The layers were separated, and the organic phase was dπed (magnesium sulfate), filtered, and concentrated. The crude matenal obtained (0.565 g) was puπfied by column chromatography on silica gel (eluant: chloroform to 3% MeOH in chloroform) to afford the titled compound (0 415 g, 70% yield)
EXAMPLE 71 was prepared according to the procedures descπbed in Example 70. but using allyl bromide. EXAMPLE 72
3-(2-(5-benzylox v- 1 -(2-(4-pyndιn vPkthvPmdolinvPmethylthioacetamidobenzoic acid
Step l - Ethyl 3-(2-(5-benzyloxy- l-(2-(4- pyndinypethvPindolinvPmethylthioacetamidobenzoate
To a solution of ethyl 3-(2-(5-benzyloxy)ιndolιnyl)methylthιoacetamιdobenzoate (0.30 g, 0.63 mmol), prepared in step 6 of Example 17, in dichloromethane (3.0 mL) and acetic acid (2.0 mL), 4-vmyIpyπdιne (0 08 mL, 0 75 mmol) was added The reaction was st ed at room temperature overnight The reaction was quenched with half saturated sodium bicarbonate, extracted with ethyl acetate (3X), dπed over magnesium sulfate and concentrated. The crude matenal was punfied on silica gel using a gradient of 2.1 hexane:ethyi acetate to 100% ethyl acetate to yield 0.023 g of product (25 %, TLC = 0 7 Rf in ethyl acetate).
Step 2
The titled compound was prepared according to the procedure descnbed in step 3 of Example 59.
EXAMPLE 73
3-(2-(5-benzyloxy-l -(2-naphthyl)methy)ιndolιnvPmethylthιoacetamιdobenzoιc acid
Step 1 - Ethyl 3-(2-(5-benzyloxy-l -(2- naphthvPmethv)ιndolιnyl)methylthιoacetamιdobenzoate
A mixture of 3-(2-(5-benzyloxy)ιndoiιnyl)methylthιoacetamιdobenzoate (0 2g,
0 42 mmol), prepared in step 6 of Example 17, 2-(bromomethyl)naphthalene (0.1 g, 0 42 mmol) and potassium carbonate (0 17 g, 1.26 mmol) in N,N-dιmethylformamιde (2 mL) was st ed at room temperature overnight Next the reaction was diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dπed over magnesium sulfate and concentrated. The crude material was purified on silica gel using 2:1 hexane:ethyl acetate to yield 0.22 g of product (85 %. TLC = 0.5 Rf in 2: 1 hexane:ethyl acetate).
Step
The titled compound was prepared according to the procedure described in step 3 of Example 59.
EXAMPLES 74 and 75 in Table 6 were prepared according to the procedures described in
Example 73.
EXAMPLE 76
2-(2-(-5-Benzyloxy- 1 -(2-naphthyl)methvPindolinvPmethylthiobenzoic acid
Step 1 : 2-(2-(-5-Benzyloxy- 1 -( 1.1 -dimethvPethoxycarbonvPindolinyl )methyl methylsulfonate
tert-Butyl l -(5-benzyloxy-2-hydroxymethy)lindolinylformate (6.72 g, 19 mmol), prepared in step 2 of Example 17, was dissolved in CH2C1 (80 mL, dried over MgS04 before use). The clear yellow solution was cooled in a dry-ice bath. Et,N (4.0 mL) was then added followed by methanesulfonyl chloride (2.0 mL). The reaction mixture was stined for 2 h at -40 °C then quenched with H20. It was washed with satuarated NaHC03
(300 mL) and the aqueous layer extracted twice with CH2C12. The combined CH2CI2 layers were dried over MgS04, filtered and evaporated to dryness to give the product (7.30 g, 89.1 % yield), which was used for the next reaction directly.
Step 2: Methyl 2-(2-(5-Benzyloxy-l-(l .l-dimethyl)ethoxycarbonvPindolinvPmethylthio benzoate
Mesylate (7.2 g, 1.8 mmol), prepared in step 1 , was dissolved in DMF (50 mL). The clear light brown solution was degassed by vigorously bubbling with Ar for 30 min. Cesium carbonate ( 13.8 g) was added followed by methyl thiosalicylate (2.4 L). The solution changed to a bright yellow and the suspension was stined overnight. Methyl thiosalicylate (0.15 mL) was added to complete the reaction and the mixture was stined overnight. The reaction was then quenched by the addition of saturated NaHCO, (400 mL). The mixture was extracted with CH2C12 (3 x) and the combined CH TK solution was back-washed with H20 (200 L). The organic layer was dried over MgS0 , filtered and evaporated to dryness to give the product (9.71 g, 99%).
Step 3: Methyl 2-(2-(5-Benzγloxy)indolinyl)methylthiobeπzoate
Ethyl acetate (75 mL, dried over MgS04 before use) was charged in a 500 mL round bottom flask. HCl gas was bubbled through and the EtOAc/HCl solution was cooled in an ice bath. Methyl ester (8.4 g), prepared in step 2, was dissolved in EtOAc (25 mL, dried over MgS04 before use). This solution was transfened to the HCl/EtOAc solution by syringe. The solution turned to red and was stined in an ice bath. A white precipitate appeared in 1 h and the solution was stined overnight to complete the reaction. The solid was collected by filtration, washed with dry EtOAc, suspended in saturated NaHCϋ3 ( 175 mL) and stined with EtOAc (400 mL). The milky emulsion gradually dissolved and the mixture changed to a clear solution. The layers were separated and the aqueous layer was extracted (2 x) with EtOAC, while the combined EtOAC layers were dried over MgS04, filtered and evaporated to dryness to give the product (6.06 g, 90 % yield).
Step 4: Methyl 2-(2-(5-Benzyloxy- l -(4-benzvPbenzvPindolinyl)methylthiobenzoate
In a 50 mL round bottom flask, ester ( 1 g), prepared in step 3, was dissolved in
DMF (6 mL). p-Benzylbenzyl bromide was added ( I eq) followed by K2CO, ( 1 eq). The reaction mixture was stined overnight at room temperature. To complete the reaction additional p-benzylbenzyl bromide (0.5 eq) was added and the reaction was stined for another 2 hours. After its completion, the reaction was diluted with H20 and extracted with EtOAc (2 x). The organic layers were combined and dried over MgS04. The MgS04 was filtered and the solvent was evaporated to give an oily material which was dried overnight on high vacuum to give the product ( 1.59 g, 109 % yield). Step 5
The ester ( 1 52 g), prepared in step 4, was dissolved in THF ( 10 mL) in a 50 mL round bottom flask To it was added NaOH ( I eq, 2N) followed by MeOH (3 mL) and the reaction mixture was st ed overnight Additional NaOH (0 3 eq) was added to complete the reaction and the mixture was stined throughout the weekend Then it was acidified and diluted with H20 and extracted with EtOAc (2 x) The organic layers were combined and dned over MgS0 The MgS0 was filtered and the solvent was evaporated and dπed on high vacuum to give a crude reddish solid. This solid was dissolved in EtOAc and hexane was added to precipitated the product The resulting solid was filtered and the impure filter cake was combined with the filtrate and evaporated to dryness This matenal was treated with EtOAc and EtOH The resulting solid was filtered then suspended in EtOH, with stimng and heating at a low temperature Then it was allowed to cool to room temperature The suspension was filtered and washed with EtOH to give the titled product (280 mg, 19 % yield)
EXAMPLES 77. 78 and 79 in Table 6 were prepared according to the procedures descπbed in Example 76
EXAMPLE 80
4-( l -(5-Benzyloχy-2-(bιs-2.4-tπfluoromethyl)benzyloxymethvPιndolιnvPmethylbenzoιc
Step 1 Methyl l -(5-Benzyloxy-2-(hvdroxymethvPιndolιnyl)methylbenzoate
2-(5-Benzyloxy)ιndolιnylmethanol (3 21 g, 126 mmol), prepared in DMF (20 mL), methyl 4-(bromomethyI)benzoate (2.88 g, 14 5 mmol) and potassium carbonate ( 1 77 g, heated to 125 °C before use) were mixed and stined at room temperature for 2 h The reaction was diluted with 100 mL of H,0 and extracted three times with EtOAc The combined EtOAc layers were evaporated to dryness to give the crude product (5 66 g) The crude matenal was punfied on a silica gel column using hexane ethyl acetate 3 I to 2 1 The appropπate fractions were combined, evaporated to dryness and further dried on high vacuum to the product (3 00 g, 64%)
Step 2 Methyl 4-( l -(5-Benzyloxy-2-(bιs-2,4-tnfluoromethyl)ben7yloxymethyl)ιndolιnyl) methylbenzoate
Ester (700 mg), prepared in step 1 , and bιs-(2,4-tπfluoromethyl)benzyl bromide (0 35 mL) were dissolved in DMF (5 mL) The resulting clear yellow solution was cooled in an ice bath and then NaH (85 mg) was added in small portions over a peπod of 5 minutes The suspension was st ed at 0 υC for 4 h To complete the reaction, another
0 35 mL of 2,4-bιs(tπfluoromethyl)-benzyi bromide was added and the stimng was continued for another 3 h 40 mm The reaction was then diluted with H20 and extracted three times with EtOAc The combined EtOAc layers were evaporated to give a crude product which was then puπfed on a silica gel columnusing hexane ethyl acetate 8 1 The appropnate fractions were combined and evaporated to dryness to give the product (0 417 g, 38 2 % yield)
Step 3
The titled compound was prepared according to the prodedure descπbed in step 5 of Example 76
EXAMPLES 81 and 82 in Table 6 were prepared according to the procedures descπbed in Example 80
EXAMPLE 83
5-(2-(l -(2.4-Bis(trifluoromethyl)benzyPindolinyl)carboxamido-1.3-benzenedicarboxylic acid
Step 1 : 2-(l -(2.4-Bis(trifluoromethvPbenzyl)indolinyl)carboxylic acid
2-Indolinylcarboxylic acid (0.43 g, 2.6 mmol) was dissolved in DMF (5 mL), placed under N,, and cooled to 0° C, the sodium hydride (0.26 g of a 60 % dispersion, 6.5 mmol) was added and stirring was continued for 1 hour at this temperature. 2,4-
Bis(trifluoromethyI)benzyl bromide (1.22 mL, 6.5 mmol) was next added and the reaction was warmed to room temperature overnight. The reaction was then diluted with 1/2 saturated ammonium chloride/ethyl acetate, the aqueous layer was extracted with ethyl acetate (3X), the organic layers were dried over magnesium sulfate and concentrated. The crude product was purified via chromatography (hexane:ethyl acetate 9:1 ) to yield 0.96 g of the ester. The resulting ester (0.87 g, 0.1.41 mmol) was dissolved in THF/ methanol and then I N sodium hydroxide (4.21 L) was added and the resulting mixture was stmed 2 hours at RT, workup and purification via Chromatography (7: 1 hexane:ethyl acetate with 1 % acetic acid) yielded 0.58 g of the product.
Step 2:
The acid (0.25 g, 0.64 mmol), prepared in step 1 , EDCI (0.16 g, 0.83 mmol), DMAP (7 mg, 0.06 mmol) and dimethyl 5-aminoιsophthalate (0.16 g, 0.77 mmol) were dissolved in THF (2 mL) and refluxed 16 hours which yielded after aqueous workup 0.33 g of a crude product. The ester (0.29 g, 0.50 mmol) was dissolved in THF/ methanol and then IN sodium hydroxide (1.5 mL) was added and the resulting mixture was stined 16 hours at RT, workup and purification via Chromatography (1: 1 hexane:ethyl acetate with 1 % acetic acid) yielded 0.22 g of the titled compound.
EXAMPLE 84
N-Methylsulfonyl-2-(l -(2.4-bis(trifluoromethvPbenzvPindolιnyl)carboxamide The acid (0 13g, 0 32 mmol), prepared in step 1 of Example 83, EDCI (0 07 g, 0 39 mmol), DMAP (4 mg, 0.03 mmol) and methylsuifonanihde (004 g, 0 39 mmol) were dissolved THF (5 mL) and refluxed 16 hours which yielded after workup (0 16 g), punfication via Chromatography (98 2 dichloromethane methanol) yielded 0 04 g of the titled compound (29%)
EXAMPLE 85
N-Phenylsulfonyl-2-( l-(bιs-2.4-trιfluoromethyl)benzvPιndolιnyl)carboxamιde
The titled compound was prepared according to the prodedure descπbed in Example 84, but using phenylsulfonylamide
EXAMPLE 86
5-(2-(5-Methoxybenzyloxy- 1 -(2.4- bιs(tπfluoromethvPbenzyl)ιndolιnyl)methylamιnocarboxamιdo-1.3-benzenedιcarboxylιc acid
Step 1 2-Tπmethylsιlylethyl l -(5-benzyloxy-2-hvdroxymethvPιndolιnylformate
An oven-dned 1 L round bottom flask, equipped with a stir bar was charged with
2-(5-benzyloxy)ιndoIιnylmethanol (33.2 g, 130 mmol), prepared in stepl of Example 17. 2-(tnmethylsιlyI)ethyl p-nitrophenyl carbonate 36 8 g, 130 mmol), NEt, (38 ml, 273 mmol), and 300 mL of anhydrous DMF The reaction mixture was st ed at 60 °C for 28 hours and at room temperature overnight The resulting solution was concentrated to dryness in vacuo, and 1 L of CHCl, and 200 mL of saturated NaHCO, solution were added The layers were separated, and the organic phase was dπed (Na,S0 ), filtered, and concentrated The crude matenal obtained (55 7 g) was punfied by column chromatography on silica gel (eluant 0-5 % MeOH in dichloromethane) to afford product (33.5 g, 60% yield) Step 2: 2-Trimethylsilylethyl l-(5-hvdroxy-2-hvdroxymethyl)indolinylformate
An oven-dried 500 mL Pan pressure flask was charged with the alcohol (30 g, 75 mmol), prepared in step 1, Pd/C (10 %, 2.2 g), 100 L of MeOH, and 300 mL of EtOAc. After being shaken overnight in a Parr apparatus under H2 atmosphere (50 psi), the reaction mixture was filtered through Florisil. The filtrate was concentrated to dryness on the rotary. The crude material obtained (24 g) was purified by column chromatography on silica gel (eluant: 0-3 % MeOH in dichloromethane) to afford product (20.9 g, 90% yield).
Step 3: 2-Trimethylsilylethyl l -(5-(4-methoxy)benzyloxy-2- hvdroxymethvPindolinylformate
An oven-dried 1 L round bottom flask, equipped with a stir bar was charged with the diol (27.1 g, 87.7 mmol), prepared in step 2, 4-methoxybenzyl chloride (Aldrich, 1 mL, 1 10 mmol), K2C03 (200 mesh, 30.4 g, 220 mmol), KI (Aldrich, 18.3 g, 1 10 mmol), and 800 mL of anhydrous acetonitrile. The reaction mixture was heated at reflux for 4 h. The solution was allowed to cool to room temperature and water (800 L) and CHCl, (1.5 L) were added. The layers were separated, and the aqueous phase was extracted with CHC13 (800 L). The combined extracts were washed with water (200 mL), dried (Na2S04), filtered, and concentrated. The crude material obtained (45 g) was purified by column chromatography on silica gel (eluant: 20-25 % EtOAc in hexane), and recrystallization from EtOAc/Hexane to afford product (22.2 g, 59% yield).
Step 4: 2-Trimethylsilylethyl l -(5-(4-methoxy)benzyloxy-2- bromomethvPindolinylformate
To a solution of 3.0 g (6.4 mmol) of the alcohol, prepared in step 3, in 30 mL of dichloromethane was added 2.53 g (7.6 mmol) of carbon tetrabromide and 3.15 g (7.6 mmol) of 1 ,3-bis(diphenylphosphino)propane. The reaction was stined at room temperature for 18 h. The reaction was quenched with saturated aqueous NH C1, and the product was extracted with dichloromethane. The combined organic extracts were washed with brine and dried over MgS04. The crude product was purified by flash chromatography using hexane:ethyl acetate 3:2 to afford 1.51 g of the product. Step 5: 2-Trimethylsilylethyl l-(5-(4-methoxy)benzyloxy-2- azidomethvPindolinylfoπnate
To a solution of 1.4 g (2.6 mmol) of the bromide, prepared in step 4, in 15 mL of dimethylformamide was added 0.51 g (7.9 mmol) of sodium azide. The reaction was heated to 75 °C, and was stined for 18 h. The reaction was quenched with water, and the product was extracted with ethyl acetate. The combined organic layers were washed with water, brine and dried over MgS0 . The crude product was purified by flash chromatography using hexane:ethyl acetate 4: 1 to afford 1.08 g of the product.
Step 6: 2-Trimethylsilylethyl l -(5-(4-methoxy)benzyloxy-2- aminomethvDindolinylformate
To a solution of 0.88 g ( 1.9 mmol) of the azide, prepared in step 5, in 20 mL of ethanol was added 90 mg ( 10%/wt) of Pd CaCO,. The mixture was placed under atmospheric hydrogen, and was stined for 18 h. The reaction was then filtered through a pad of celite and the organic phase was concentrated. The crude product was purified by flash chromatography using 10% MeOH/CH2Cl2 to afford 0.717 g of the product.
Step 7: Methyl 5-(2-(5-Methoxybenzyloxy- l -(2- trimethylsilyloxy)ethoxycarbonv)lindolinyl) methylaminocarboxamido-1.3- benzenedicarboxylate
To a solution of 0.164 g (0.6 mmol) of triphosgene in 5 mL of dichloromethane was added a solution of 0.31 g (1.5 mmol) of dimethyl-5-aminoisophthalate and 0.39 g
(3.0 mmol) of diisopropylethylamine in 20 mL of dichloromethane over a 30 minute period via a syringe pump. The reaction was stined for 1 h at room temperature following the addition, and then a solution of 0.64 g ( 1.5 mmol) of the amino, prepared in step 6, in 5 mL of dichloromethane was added in one portion. The reaction was stined for 2 h, and then quenched with water. The product was extracted with ethyl acetate, and the combined organic layers were washed with water, saturated aqueous NaHCO,, brine and dried over MgS0 . The crude product was purified by flash chromatography using 10% MeOH/CH2Cl2 to afford 0.78 g of the product. Step 8 Methyl 5-(2-(5-Methoxybenzyloxy)ιndolιnyl)methylamιnocarboxamιdo-1.3- benzenedicarboxylate
To a solution of 0 485 g (0 7 mmol) of the ester, prepared in step 7, in 20 mL of acetonitπle was added 2 2 mL (2.2 mmol) of a 1.0 M tetrabutylammonium fluoπde solution in THF The reaction was stined at room temperature for 18 h The reaction was quenched with bπne, and the product was extracted with ethyl acetate. The combined organic extracts were washed with saturated aqueous NH4C1, bπne and dπed over MgS04 The crude product was punfied by flash chromatography using 5% MeOH/CH,Cl2 to afford 0.342 g of the product
Step 9 Methyl 5-(2-(5-Methoxybenzyloxy- l -(bιs-2.4-tnfluoromethyl)benzvPιndolιnvP eth ylaminocarboxamido- 1.3-benzenedιcarboxylate
To a solution of 0.15 g (0.3 mmol) of the indoline diester, prepared in step 8, in 5 mL of dimethylformamide was added 0.097 g (0.3 mmol) of 2,4- bιs(trifluoromethyl)benzyl bromide and 0.12 g (0.9 mmol) of potassium carbonate The reaction was stmed at room temperature for 18 h. The reaction was quenched with water, and the product was extracted with ethyl acetate The combined organic extracts were washed with water, bπne and dπed over MgS04 The crude product was punfied by flash chromatography using hexane:ethyl acetate 1 : 1 to afford 0.066 g of the product.
Step 10
To a solution of 0.063 g (0.1 mmol) of the diester, prepared in step 9, in 5 mL of tetrahydrofuran was added 0.8 mL (0.8 mmol) of a 1 0 N NaOH solution and 0 5 mL of methanol. The reaction was stmed at room temperature for 18 h. The organic solvents were evaporated, and the resulting solid was suspended in water and acidified to pH 3 with 10% HCl The product was extracted with ethyl acetate, and the combined organic extracts were washed with water, brine and dned over MgS04. The crude product was puπfied by flash chromatography using 5% MeOH CH2Cl2 to afford 0.049 g of the titled compound. EXAMPLE 87 was prepared according to the prodedure descπbed in Example 86. but using 4-(3,5-bιs(tnfluoromethyl)phenoxymethyl)benzyl bromide.
INTERMEDIATE 1
Methyl 4-methoxy-3-thιoacetamιdobenzoate
Step 1 : Bιs(methyl 4-methoxy-3-dιthιoacetamιdobenzoate)
A 2-L oven-dned round bottom flask fitted with a magnetic sti ng bar was charged with Dithioacetic acid ( 10.2- 15 5 g, 56-85 mmol) and anhydrous CH,C12 (50 mL)
Oxalyl chlonde (2.1 mol equiv.) was added dropwise over 10 min. The reaction mixture was stmed at room temperature for 4-5 h Methyl 4-methoxy-3-amιdobenzoate (2.1 mol equiv.) in anhydrous CH2C12 (300-500 mL) and DMAP (0 1 mol equiv ) were added at room temperature. NEt3 (4.2 mol equiv.) was added dropwise over 30 min. After stirnng overnight at room temperature the reaction mixture was washed with 1 N HCl solution (2 x
300 mL), dπed over Na2S04 and filtered. The solvent was removed in vacuo Punfication of the residue by column chromatography on silica gel using hexane:ethyl acetate = 5 1 afford desired product in 56% yield
Step 2:
A 1-L round bottom flask fitted with a magnetic stimng bar was charged with disulfide, prepared in step 1 , ( 15.7-26.3 g, 36.6-57.5 mmol) and PPh, (1.1 mol equiv.). The reactants were suspended in dιoxane/H,0 (4/1, 375-500 mL) and concentrated HCl solution (5 drops) was added. The reaction mixture was heated at 40 °C until all disulfide was consumed. Solvents were removed in vacuo. The residue was punfied immediately by column chromatography on silica gel using hexane • ethyl acetate 2.1 to afford the titled product in 89% yield. INTERMEDIATE 2
Methyl 5-thιoacetamιdo-l ,3-benzenedιcarboxylate
The titled compound was synthesized according to the procedures descπbed in
Intermediate 1 using 5-amιno-l ,3-benzenedιcarboxylate
UINTERMEDIATE 3
Methyl 2-(3-amιno-4-methoxyphenyl)-2-methoxyacetate
Step 1 Methyl 2-(3-nιtro-4-methoxyphenvPacetate
An oven-dned 2-L, 3-neck round bottom flask, equipped with a mechanical stir motor, a low-temperature thermometer and an equalizing dropping funnel, was charged with acetic anhydnde (631 mL) and subsequently cooled to -78 °C Fuming nitπc acid (Baker, 90%, 27 mL) was added dropwise via the dropping funnel protected with a drying tube filled with CaCl, After addition was completed, the reaction temperature was allowed to warm to 20 °C over 1 h. The reaction mixture was cooled to -78°C again and added 4-methoxyphenylacetιc acid (50 g, 0.28 mol) dropwise via the dropping funnel After stirnng at -50 °C for 1 h., the reaction mixture was allowed to warm to -30 °C over 20 min and then cooled to -50 °C again The reaction mixture was quenched with H20 (500 mL) at -50 °C and warmed up to room temperature and stmed for 0 5 h The reaction mixture was partitioned between CH2C12 (500 mL) and H,0 The aqueous layer was extracted with CH,CI, (3 x 500 mL) The combined CH2C12 extracts were concentrated in vacuo to give a yellow oil This was added slowly to a 2 M solution of NaOH (2 L) cooled at 0 °C and stined at room temperature overnight The reaction mixture was partitioned between CH2CL (500 mL) and H20 The aqueous layer was extracted with CH2C1, (3 x 500 mL) The combined CH2C12 extracts were stmed with 2 M NaOH solution (1 L) for 1 h. The layers were separated and the organic layer was washed with H20 (500 mL), bπne (500 mL), dπed over Na,S0 and filtered. The solvents were removed in vacuo to afford crude product as a light yellow solid (56 g) Punfication by recrystalhzation from MeOH (600 L) gave product. Yield 48 g (77%). Step 2 Methyl 2-(3-nιtro-4-methoxyphenvP-2-hvdroxyacetate
A 25-mL oven-dned round bottom flask fitted with a magnetic stimng bar was charged with ester (2.3 g, 10 mmol), prepared in step 1 , and anhydrous THF ( 100 mL) The reaction mixture was cooled to -78 "C and a solution of NaN(SiMe3)2 (1.0 M in THF,
12 mL, 12 mmol) was added dropwise over 10 mm. After stimng at -78 °C for 30 m ., the deep purple solution was added dropwise a solution of racemic camphor sulfonyloxaziπdine (3 4 g, 15 mmol), prepared by mixing the commercially available ( 1S)- (+)-(10-camphorsulfonyl)oxazιπdιne ( 1 7 g) and ( lR)-(-)-( 10-camphorsulfonyl)oxazιπdιne ( 1.7 g) in 50 L THF After stimng at -78 °C for 30 min., the reaction mixture was quenched with sat. NH4C1 solution (45 mL) at -78 °C and then allowed to warm to room temperature. The reaction mixture was partitioned between ether (250 mL) and H20 (50 mL) The aqueous layer was extracted with ether (3 x 250 mL). The combined ether extracts were washed with bπne (250 mL), dπed over Na,S04 and filtered The solvents were removed in vacuo. Punfication by column chromatography on silica gel (eluant: 50%
AcOEt in hexane) afforded desired product. Yield 2.2 g (88%).
Step 3. Methyl 2-(3-nιtro-4-methoxyphenvP-2-methoxyacetate
A 10-mL oven-dned round bottom flask fitted with a magnetic stimng bar was charged with alcohol (0.30 g, 1.24 mmol), prepared in step 2, Ag20 (0 68 g, 3.0 mmol) and toluene (3 mL). To this was added CH,I (0.36 g, 5 75 mmol) dropwise. The reaction flask was capped tightly and placed into a sonication chamber. The reaction mixture was sonicated for 18 h while stirnng at room temperature. The reaction mixture was filtered through Celite and concentrated in vacuo to dryness The residue was puπfied by column chromatography on silica gel (eluant: 30% AcOEt in hexane) to afford desired product Yield 0.26 g (82%).
Step 4
A 100-mL oven-dned round bottom flask fitted with a magnetic stimng bar and a three way adapter, connecting to a hydrogen balloon and a water aspirator was charged with nitro compound (0.7 g, 2.6 mmol), 5% Pd on Carbon (10% by weight) and MeOH (20 mL). The reaction flask was placed under vacuum via the water aspirator and subsequently filled with H2 This was repeated three times The reaction mixture was stmed for 18 hours under positive H2 pressure until all starting matenal was reacted The reaction mixture was filtered through Cehte and concentrated in vacuo to dryness The residue was punfied by column chromatography on silica gel using 10% ethyl acetate in dichloromethane to afford the titled compound (0.57 g, 97%)
INTEMEDIATE 4
Methyl 2-(3-amιno-4-methoxyphenvP-2-tert-butyldιmethylsilyloxyacetate
A 25-mL oven-dned round bottom flask fitted with a magnetic stimng bar was charged with alcohol (0 30 g, 1.24 mmol), prepared in step 2 of Intermediate 3 and anhydrous CH,CI2 ( 10 mL) The reaction mixture was cooled to 0 °C and added 2,6- lutidme (dπed over NaOH pellet, 0.36 mL, 3.1 1 mmol) followed by addition of
'BuMe2SιOTf (0.43 mL, 1.87 mmol) dropwise After stimng at 0 °C for 30 mm., the reaction mixture was partitioned between CH,C1, (20 mL) and H20 (15 mL). The aqueous layer was extracted with CH2C12 (3 x 20 mL). The combined CH2C12 extracts were washed with bnne (20 mL), dried over Na,S04 and filtered. The solvents were removed in vacuo Punfication by column chromatography on silica gel (eluant: 30% AcOEt in hexane) afforded desired product Yield 0.42 g (95%)
Step 2-
The titled compound was prepared from nitro compound of step 1 according to the procedure descπbed in step 4 of Intermediate 3
INTERMEDIATE 5
Methyl 2-(3-amιno-4-methoxyphenvPacetate
The titled compound was prepared from nitro compound, prepared in step 1 of Intermediate 3, according to the procedure descπbed in step 4 of Intermediate 3 INTERMEDIATE 6
Methyl 2-(3-amιno-4-methoxyphenyl)-2-methylacetate
Step 1 Methyl 2-(3-nιtro-4-rnethoxyprtenyl)-2-methylacetate
A 25-mL oven-dned round bottom flask fitted with a magnetic stimng bar was charged with redistilled dnsopropyiamine (0 84 mL, 6.0 mmol) and anhydrous THF (10 mL) and cooled to 0 °C. A solution of n-BuLi (2.5 M in hexane, 2 4 mL, 6.0 mmol) was added dropwise over 5 min After stimng at 0 °C for 15 min., the reaction temperature was allowed to cool to -78 °C and added a solution of easter ( 1.13 g, 5.0 mmol), prepared in step 1 of Intermediate 3, in 10 mL THF dropwise After stimng at -78 °C for 45 mm., dimethylsulfate ( 1.60 g, 12.5 mmol) was added dropwise and the reaction mixture was allowed to warm to room temperature and stmed overnight. The reaction mixture was partitioned between CH2C12 (50 L) and H20 (50 mL) The aqueous layer was extracted with CH2C1, (3 x 50 mL). The combined CH2C12 extracts were washed with bπne (50 mL), dπed over Na2S04 and filtered. The solvents were removed in vacuo. Punfication by column chromatography on silica gel (eluant: 30% AcOEt in hexane) afforded 0 7 g of product (58%).
Step 2
The titled compound was prepared from nitro compound, prepared in step 1 , according tothe procedure descnbed in step 4 of Intermediate 3.
INTERMEDIATE 7
Methyl 2-(3-amιno-4-methoxyphenvP-2-allylacetate
Step 1 Methyl 2-f3-nιtro-4-methoxyphenvP-2-allylacetate
This compound was synthesized form ester, prepared in step 1 of Intermediate 3, according to the procedure descnbed in step 1 of Intermediate 6, but using allyl bromide.
Step 2
A 25-mL oven-dned round bottom flask fitted with a magnetic stimng bar was charged with ester (0 30 g, 1 13 mmol), prepared in step 1 , SnCI, 2H20 ( 1 28 g, 5.66 mmol) and EtOH (5 mL) The reaction mixture was heated at 70 °C for 30 min The reaction mixture was cooled to room temperature and poured onto ice/water (20 mL) and basified with saturated Na2CO, solution to pH = 8 AcOEt (50 mL) was added The resulting emulsion was filtered through Celite The filtrate was partitioned between AcOEt (20 mL) and H,0 ( 15 mL) The aqueous layer was extracted with AcOEt (3 x 50 mL) The combined AcOEt extracts were washed with bπne (50 mL), dned over Na2S04 and filtered The solvents were removed in vacuo Punfication of the residue by column chromatography on silica gel (eluant. 10% AcOEt in CH,C1,) afforded the titled compound Yield 0 16 g (60%)
INTERMEDIATE 8
2.4-Bιs(l .l -dιmethvpropyPphenoxyacetιc acid
The 2,4-bιs(l ,l-dιmethy)propylphenol ( 12 g, 51 2 mmol) in dimethylformamide (100 mL) was cooled to -30° C, treated with solid potassium bιs(tπmethylsιlyl)amιde
(12.3g, 61 5 mmol), stmed for 30 minutes and then methyl bromoacetate (5 7 mL, 61 5 mmol) was added, the reaction was stmed 1 hour at this temperature and five hours after removal of the cooling bath, workup yielded (16 6g, = 100%) a yellow oil The oil was dissolved in THF/methanol and treated with IN sodium hydroxide (155 mL) and stmed for 48 hours. The reaction was concentrated, diluted with water, acidified to pH 4 with concentrated HCl, extracted with ethyl acetate (4X), dπed over magnesium sulfate and concentrated. Crystaiization from ethyl acetate and hexane yielded 12.85 g of the titled compound (86%).
INTERMEDIATE 9
4-Benzylphenoxyacetιc acid
The titled compound was prepared from 4-benzylphenol according to the procedure descnbed in of Intermediate 8.
INTERMEDIATE 10
2-Naphthoxyacetιc acid
The titled compound was prepared from 2-naphthol according to the procedure descπbed in of Intermediate 8.
INTERMEDIATE 1 1
3,5-Bιs(trifluoromethyl)phenoxyacetιc acid
The titled compound was prepared from 3,5-bιs(tπfluoromethyl)phenol according to the procedure descπbed in of Intermediate 8.
INTERMEDIATE 12
Methyl 5-amιno-3-(N.N-dιmethvPcarbamoylbenzoate
Step 1 Methyl 5-nιtro-3-(N.N-dιmethvPcarbamoylbenzoate A 100-mL oven-dned round bottom flask fitted with a magnetic stimng bar was charged with 5-mtro-3-methoxycarbonylbenzoιc acid (3.15 g, 10 mmol), DMF ( 1 drop), anhydrous CH2C12 (70 L), and oxalyl chlonde (3.7 mL, 42.3 mmol). The reaction mixture was stined at room temperature for 2 h. The solvent was removed in vacuo to afford acid chloπde as a white solid. This was used immediately in the next step without further punfication.
An oven-dned round bottom flask fitted with a magnetic stimng bar was charged with above prepared acid chloπde (14 mmol), anhydrous CH2C12(50 mL), and dimethyiamine hydrochlonde (70 mmol). NEt3 (2 mL, 144 mmol) was added dropwise. After stimng at room temperature for 30-60 min excess NEt, (1 mL, 72 mmol) was added and stirring was continued. After 30-60 min the solution was washed with saturated Na2C03 solution (2 x 20 mL), dried over Na^Oj and filtered. The solvent was removed in vacuo to afford 3.3 g of product. This was used in the next step without further punfication.
Step 2-
The titled compound was prepared from nitro compound, prepared in step 1 , according to the procedure descπbed in step 4 of Intermediate 3.
INTERMEDIATE 13
Methyl 5-amιno-3-acetylbenzoate
Step 1 - Methyl 5-nitro-3-acetylbenzoate
A 250-mL oven-dried round bottom flask fitted with a magnetic stimng bar was charged with di-tert-butyl malonate (2.16 g, 10 mmol), anhydrous toluene (50 mL), and NaH (60% suspension in mineral oil, 0.88 g, 22 mmol). The reaction mixture was heated at
80 °C for 1 h. A solution of methyl 5-nitro-3-chIoroformylbenzoate ( 10 mmol), prepared in step 1 of Intermediate 12, in anhydrous toluene (20 mL) was added and heating was continued for 2 h. The reaction mixture was cooled to room temperature and p- toluenesulfonic acid (0.21 g, 1.2 mmol) was added. The resulting mixture was filtered and the oily residue was washed with toluene until a white solid was left The filtrates were combined and the solvent was removed in vacuo The resulting oil was dissolved in anhydrous toluene (50 mL) and p-toluenesulfonic acid (0 3 g, 1 74 mmol) was added After heating to reflux for 18 h the reaction mixture was allowed to cool to room temperature, washed with saturated Na^COj solution (2 x 25 mL), dned over Na2S04 and filtered. The solvent was removed in vacuo The crude matenal was punfied by column chromatography on silica gel (eluant. CH2C12) to afford product Yield 1.06 g (50%)
Step 2
The titled compound was prepared from nitro compound, prepared in step 1 , according to the procedure descπbed in step 4 of Intermediate 3
INTERMEDIATE 14
Methyl 5-amιno- (1 -tert-butyldιmethylsιlyloxy ethylbenzoate
Step I Methyl 5-nιtro-3-( l -hydroxy)ethylbenzoate
An oven-dned round bottom flask fitted with a magnetic stimng bar was charged with compound methyl 5-nιtro-3-acetylbenzoate (0,5 g), prepared in step 1 of Intermediate 13, BH3 THF (1 M solution in THF, 5 mol equiv ), and anhydrous THF After stimng at room temperature for 24 h, H20 (20 mL) was added and the solution was concentrated in vacuo The residue was taken in H20 (20 mL) and extracted with CHCI3 (3 x 100 mL)
The combined CHCl, extracts were washed with saturated Na2C03 solution (20 mL), dned over Na2S04 and filtered. The solvent was removed in vacuo to afford product This was used in the next step without further punfication.
Step 2 Methyl 5nιtro-3-(l -tert-butyldιmethylsιlyloxy)ethylbenzoate
An oven-dned round bottom flask fitted with a magnetic stimng bar was charged with alcohol (0 5g, 5 mmol), prepared in step 1 , tert-BuMe2SιCl ( 1 3 mol equiv ), lmidazole (2.1 mol equiv.), and anhydrous THF After stirnng at room temperature for 28 hours the solvent was removed in vacuo. The residue was taken H:0 (50 mL) and extracted with CHC13 (2 x 100 mL). The combined CHCl, extracts were washed with H20 (50 mL), dπed over Na,S04and filtered. The solvent was removed in vacuo. The crude matenal was punfied on silica gel using 25%-50% dicloromethane in hexane to afford the product (0.69 g, 91 %)
Step 3-
The titled compound was prepared from nitro compound, prepared in step 2, according to the procedure described in step 4 of Intermediate 3.
INTERMEDIATE 15
Methyl 4-methoχy-3-(2-thιoethyl)amιnobenzoate
Step 1. Bιs(2-bromoethvPdisulfide
The dithioethanol (0 79 mL, 6.48 mmol), carbon tetrabromide (4.3 g, 13.0 mmol) and 1 ,3 bιs(dιphenylphosphιno)propane (5.34 g, 13.0 mmol) were weighed into a flask and flushed with nitrogen and then taken up in CH2C12 (15 mL) and stmed for 16 hours, workup consisted of pouπng into 1/2 saturated ammonium chloπde and extracted with CH2C12 (3X) dry magnesium sulfate and concentrated to yield (90 g) of a crude product that was chromatographed (Hexane:Ethyl acetate9.1 ) to yield I 49 g of product.
Step 2: Bιs-( methyl 4-methoxy-3-(2-dithιoethyl)amιnobenzoate
Bromide (0.39 mg, 1.387 mmol), prepared in step 1 , and methyl 3-amino-4- methoxy benzoate (1.00 g, 5.51 mmol) were added into a flask, flush with nitrogen and take up in DMF (5 mL) and then heat to 60 ° C for 24 hours at which time the reaction was diluted with ethyl acetate and quenched into water, extracted with ethyl acetate (3X), the combined organic layers were washed with water (3X), dπed and concentrated to yield 1.27 g of a product that was purified by chromatography (hexane:ethyl acetate 5.1 to 3: 1 ) to yield 0.15 g of the desired product. Step 3:
The disulfide (0.15 g, 0.24 mmol), prepared in step 2, and the triphenylphoshpine (0.14 g, 0.53 mmol) were taken up in THF (3 mL). H20 (0.3 mL) and two drops of cone. HCl were added and the resulting mixture was stined at 40 " C for 2 hours, the reaction was diluted with water and ethyl acetate, extracted with ethyl acetate (3 X) and dried over magnesium sulfate to yield 0.27 g of a crude product that was purified by chromatography (hexane:ethy 1 acetate 9: 1 to 6: 1 ) to yield 0.1 1 g of the titled compound.
Example 88 Activity Assays
(a) Vesicle Assay l-palmitoyl-2-[, C] arachidonyl phosphotidylcholine (58 mCi/mmol) (final concentration 6 μM) and 1 ,2-dioleyolglycerol (final concentration 3 μM) were mixed and dried under a stream of nitrogen. To the lipids was added 50 mM Hepes pH 7.5 (2x final concentration of lipids) and the suspension was sonicated for 3 min. at 4°C. To the suspension was added 50 mM Hepes pH 7.5, 300 mM NaCl, 2 mM DTT, 2 mM CaCl2 and 2 mg/ml bovine serum albumin (BSA) (Sigma A751 1 ) ( 1.2x final concentration of lipids). A typical assay consisted of the lipid mixture (85 μl) to which was added consecutively, the inhibitor (5 μl in DMSO) and cPLA2, 10 ng for an automated system or 1 ng for a manual assay, in lOμl of the BSA buffer. This assay was conducted by either the manual assay or automated assay protocol described below.
(b) Soluble Substrate Assay (LvsoPO l -[' C]-palmitoyl-2-hydroxyphosphotidyl-choline (57 mCi/mmol) (final concentration 4.4 μM) was dried under a stream of nitrogen. The lipid was resuspended by vortexing 80 mM Hepes pH 7.5, 1 mM EDTA ( 1.2 x final concentration). A typical assay consisted of lipid suspension (85 μl) to which was added consecutively the inhibitor (5μl in DMSO) and cPLA2, 200 ng in 80 mM Hepes pH 7.5, 2 mM DTT and 1 M EDTA. This assay was conducted by either the manual assay or automated assay protocol described below. (c) Automated Assay
The lipid suspension and inhibitor were pre-incubated for 7 min. at 37°C. Enzyme was added and the incubation was continued for a further 30 mins. The reaction was then quenched by the addition of decane: isopropanol: trifluoroacetic acid (192:8: 1 w/v, 150 μl). A portion of the quench layer (50 μl) was passed through a Rainin Spheric-5 silica column
(5μ, 30 x 2.1 mm) eluting with heptane:methanol:TFA (97:3:0.1 v/v). The level of [l C]- arachidonic acid was analyzed by an in-line Radiomatic Flo-One/Beta counter (Packard).
(d) Manual Assay The lipid, inhibitor and enzyme mixture were incubated at 37°C for 30 min. The reaction was quenched by the addition of heptane:isopropanol:0.5M sulfuric acid ( 105:20: 1 v/v, 200 μl). Half of the quench layer was applied to a dispoable silica gel column (Whatman SIL, 1 ml) in a vacuum manifold positioned over a scintillation vial. Free [l C]- arachidonic acid was eluted by the addition of ethyl ether ( 1 ml). The level of radioactivity was measured by liquid scintillation counter.
(e) PMN Assay
PMNs were isolated using Ficoll-Hypaque according to the manufacturers directions. Red blood cells contaminating the PMNs were removed by hypotonic lysis, and the PMN pellet was washed once, and resuspended in Hanks buffered saline at a concentration of 2 x 106 cells/ml. The cells were preincubated with inhibitors for 15 min at 37 °C and then stimulated with 2 uM A23187. When monitoring LTB4 production as a measure of cPLA2 inhibition, the reaction was quenched with an equal volume of ice cold phosphate buffered saline. Cells were removed by centrifugation, and the LTB4 present in the cell supernatant was measured using the LTB scintillation proximity assay provided by
Amersham according to the manufacturers directions. In the assays reported in the Tables above, LTB4 was measured. When monitoring arachidonic acid production, the reaction was quenched with methanol containing D8-arachidonic acid as an internal reference. The lipids were extracted by the method of Bligh et al. ((1959) Can. J. Biochem. Physiol., 37, 91 1-917), and the fatty acid was converted to the pentafluorobenzyl ester and analyzed by
GC-MS in a manner similar to that reported by Ramesha and Taylor ((1991 ) Anal. Biochem. 192, 173-180). (c) Coumaπne (PGE, Production) Assay
RBL-2H3 cells were routinely cultured as 37°C in a 5% C02 atmosphere in minimal essential medium containing nonessential amino acids and 12% fetal calf serum The day before the expenment, cells were seeded into spinner flasks at 3 x \ 0 cells/ml and 100 ng/ml DNP specific-IgE was added After 20 hrs, the cells were harvested by centnfugation and washed once in serum-free minimal essential media, and resuspended to 2 x 106 ceils/ml in serum free media The cells were then premcubated with either inhibitor in DMSO (1 % v/v) or DMSO ( 1 % v/v) for 15 min at 37°C followed by stimulation with DNP-BSA (300 ng/ml) After 6 min, the cells were removed by centnfugation, and the supernatant was assayed for PGD2 content in accordance with known methods
Example 89
Rat Canageenan-Induced Footpad Edema Test
Each compound was suspended in 0.3ml absolute ethanol, 0 I ml Tween-80 and 2 0 ml Dulbecco s PBS (without calcium or magnesium). To this mixture, 0 1 ml I N
NaOH was added After solution was complete, additional amounts of PBS were added to adjust the concentration to I mg/ml All comounds remained in solution Compounds were administered I.V. in a volumne of 5 ml/kg to male Sprague Dawley rats at the same time that edema was induced by injection of 0 05ml of 1 % Type IV canageenan into the hind footpad. Footpad volume was measured before dosing with compound and 3 hours after dosing with carageenan.
All patent and literature references cited herein are incorporated as if fully set forht herein

Claims

What is claimed is
1 A compound having a chemical formula selected from the group consisting of
Figure imgf000095_0001
Figure imgf000095_0002
or a pharmaceutically acceptable salt thereof, wherein.
A is independent of any other group and is selected from the group consisting of -CH,- and -CH2-CH2-,
B is independent of any other group and is selected from the group consisting of -(CH2)„-, -(CH20)n-, -(CH2S)„-, -(OCH2)n-, -(SCH2),-. -(CH=CH)„-, -(C=C)n-, -CON(R6)-, -N(R5)CO-, -0-, -S- and -N(R6)-,
R, is independent of any other R group and is selected from the group consisting of -X-R6, -H -OH, halogen, -CN, -NO,, C,-C, alkyl, alkenyl, alkinyl, aryl and substituted aryl,
R2 is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR,, -CONR,R6, -(CH2)n-W-(CH2)m-Z-Rs, -(CH2)n-W-R„ -Z-R„ C,-Cl0 alkyl, alkenyl and substituted aryl,
R3 is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR5, -CONR5R6, -(CH2)„-W-(CH2)ra-Z-R„ (CH2)r-W-R„ -Z-R„ C,-Cl0 alkyl, alkenyl and substituted aryl,
R4 is independent of any other R group and is selected from the group consisting of -H, -OH, -OR6, -SR6, -CN, -COR6, -NHR6, -COOH, -CONR6R7, -NO,, -CONHSO R8, C,- G, alkyl, alkenyl and substituted aryl,
R5 is independent of any other R group and is selected from the group consisting of -H, -OH, -0(CH,)nR„ -SRft, -CN, -COR6, -NHR6, -COOH, -NO,, -COOH, -CONR6R7, -CONHSO,Rs, C,-C3 alkyl, alkenyl, alkinyl, aryl, substituted aryl, -CF„ -CF,CF, and
Figure imgf000096_0001
R6 is independent of any other R group and is selected from the group consisting of -H, C,-C, alkyl, alkenyl, alkinyl, aryl and substituted aryl,
R7 is independent of any other R group and is selected from the group consisting of -H, C,-C, alkyl, alkenyl, alkinyl, aryl and substituted aryl,
R8 is independent of any other R group and is selected from the group consisting of CrC3 alkyl, aryl and substituted aryl;
R9 is independent of any other R group and is selected from the group consisting of -H. -OH, a halogen, -CN, -OR6, -COOH, -CONR„R7, tetrazole, -CONHSO,RK, -COR6, - (CH,)nCH(OH)R6 and -(CH2)nCHR6Rs,
Rι0 is independent of any other R group and is selected from the group consisting of -H, -OH, a halogen, -CN, -OR6, -COOH. -CONR5R7, tetrazole, -CONHS02R8, -COR6, -(CH,)nCH(OH)R6 and -(CH2)nCHR6R„
W is, independently each time used including within the same compound, selected from the group consisting of -0-, -S-, -CH,-, -CH=CH-, -C = C- and -N(R6)-,
X is independent of any other group and is, independently each time used including with the same compound, selected from the group consisting of -O-, -S- and -N(R6)-,
Z is independent of any other group and is, independently each time used including within the same compound, selected from the group consisting of -CH,-, -O-, -S-, -N(R6)-, -CO-, -CON(R6)- and -N(Rb)CO-, m is, independently each time used including within the same compound, an integer from 0 to 4, and n is independent of m and is, independently each time used including within the same compound, an integer from 0 to 4
2. The compound of claim 1 having phospholipase enzyme inhibiting activity
3. The compound of claim 1 wherein said compound has the following chemical formula.
Figure imgf000097_0001
4. The compound of claim 1 wherein said compound has the following chemical formula:
Figure imgf000097_0002
The compound of claim 1 wherein compound has the following chemical formula:
Figure imgf000097_0003
6. The compound of claim 1 wherein A is -CH,- and R, is
-(CH,)n-W-(CH,)m-ZR,
7. The compound of claim 6 wherein n is 1 , m is 1 , W is -S- and Z is -CO-.
8. The compound of claim 7 wherein R, is -NHR6.
9. The compound of claim 8 wherein R6 is a substituted aryl group
10. The compound of claim 9 wherein said aryl group is substituted with one or more substituents independently selected from the group consisting of a halogen, -CF,, -CF2CF„ -(CH2)pCOOH, -(CH2)pCH„ -0(CH,)„CH„ -(CH2)pOH, -(CH,)pS(C6H6), -(CH2),,CONH2 and -CHRπCOOH, wherein Rn is selected froup the group consisting of alkyl, alkenyl, alkynyl, -(CH,)pOH, and -0(CH,)PCH,, and wherein p is an integer from 0 to
4
1 1 The compound of claim 6 wherein R, is selected from the group consisting of -H and -OCH,(C6Hή)
12. The compound of claim 6 wherein R, is -COR,, R, is -OCH,R6 and R6 is a substituted aryl group
13 The compound of claim 12 wherein said aryl group is substituted with one or more substituents selected from the group consisting of -CF„ -CF,CF, and -C(CH,),CH,CH,
14 A method of inhibiting the phospholipase enzyme activity of an enzyme, compπsing admimstenng to a mammalian subject a therapeutically effective amount of a compound of claim 1
15 A method of treating an inflammatory condition, compnsing admi stenng to a mammalian subject a therapeutically effective amount of a compound of claim 1
16 A pharmaceutical composition compnsing a compound of claim 1 and a pharmaceutically acceptable earner
PCT/US1997/014943 1996-08-26 1997-08-26 Inhibitors of phospholipase enzymes WO1998008818A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP10511798A JP2000516958A (en) 1996-08-26 1997-08-26 Phospholipase enzyme inhibitors
EP97938589A EP0922028A1 (en) 1996-08-26 1997-08-26 Inhibitors of phospholipase enzymes
AU40882/97A AU717430B2 (en) 1996-08-26 1997-08-26 Inhibitors of phospholipase enzymes
CA002264020A CA2264020A1 (en) 1996-08-26 1997-08-26 Inhibitors of phospholipase enzymes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70311596A 1996-08-26 1996-08-26
US08/703,115 1996-08-26

Publications (1)

Publication Number Publication Date
WO1998008818A1 true WO1998008818A1 (en) 1998-03-05

Family

ID=24824076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/014943 WO1998008818A1 (en) 1996-08-26 1997-08-26 Inhibitors of phospholipase enzymes

Country Status (5)

Country Link
EP (1) EP0922028A1 (en)
JP (1) JP2000516958A (en)
AU (1) AU717430B2 (en)
CA (1) CA2264020A1 (en)
WO (1) WO1998008818A1 (en)

Cited By (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043654A2 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO1999043651A2 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO1999043672A1 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase a2
DE19818964A1 (en) * 1998-04-28 1999-11-04 Dresden Arzneimittel New hydroxy-indole derivatives useful in treatment of degenerative joint disease, viral and parasitic infections, bronchial, dermatological, neurodegenerative and prostate disorders, etc.
EP0995742A1 (en) * 1997-06-27 2000-04-26 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
DE19917504A1 (en) * 1999-04-17 2000-10-19 Dresden Arzneimittel New hydroxy-indole derivatives, useful in treatment of degenerative joint disease, viral and parasitic infections, bronchial, dermatological, neurodegenerative and prostate disorders, etc.
US6251923B1 (en) 1998-04-28 2001-06-26 Arzneimittelwerk Dresden Gmbh Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation
WO2002000620A1 (en) * 2000-06-27 2002-01-03 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
US6414179B1 (en) 2000-02-18 2002-07-02 Bristol-Myers Squibb Company Alpha-and beta-substituted trifluoromethyl ketones as phospholipase inhibitors
WO2002053534A1 (en) 2000-12-28 2002-07-11 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
US6492550B2 (en) 2000-02-18 2002-12-10 Bristol-Myers Squibb Company Alpha-substituted thio, -oxo trifluoromethylketones as phospholipase inhibitors
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6525083B2 (en) 2000-07-25 2003-02-25 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6569539B2 (en) 1996-10-30 2003-05-27 Tetra Level Holdings & Finance S.A. Gas barrier packaging laminate method for production thereof and packaging containers
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US6686384B2 (en) 2000-12-05 2004-02-03 Aventis Pharma Deutschland Gmbh Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US6800654B2 (en) 2001-06-20 2004-10-05 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6872744B2 (en) 2001-09-27 2005-03-29 Syntex (U.S.A.) Llc Indole derivatives as anti-inflammatory agents
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6924391B2 (en) 2000-05-11 2005-08-02 Bristol-Myers Squibb Company Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors
US6924301B1 (en) 1999-10-22 2005-08-02 Shionogi & Co., Ltd. Composition for treating or preventing arrhythmia
US6933316B2 (en) 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
EP1633716A2 (en) * 2003-04-16 2006-03-15 Bristol-Myers Squibb Company Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors
US7022714B2 (en) 2002-07-31 2006-04-04 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7078429B2 (en) 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US7101903B2 (en) 2002-12-10 2006-09-05 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1)
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
EP1750730A2 (en) * 2004-05-03 2007-02-14 Ilypsa, Inc. Treatment of hypercholesterolemia, hypertriglyceridemia and cardiovascular-related conditions using phosphalipase-a2 inhibitors
US7186746B2 (en) 2002-08-29 2007-03-06 Merck & Co., Inc. Indoles having anti-diabetic activity
US7259182B2 (en) 2002-12-10 2007-08-21 Wyeth Aryl, aryloxy, and aklyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268145B2 (en) 1998-07-15 2007-09-11 Teijin Pharma Limited Thiobenzimidazole derivatives
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7323483B2 (en) 2005-01-27 2008-01-29 Wyeth Processes and compounds for the preparation of substituted naphthylindole derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7557135B2 (en) 2005-05-27 2009-07-07 Wyeth Inhibitors of cytosolic phospholipase A2
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7632955B2 (en) 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
US7691894B2 (en) 2003-07-24 2010-04-06 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US7705023B2 (en) 2004-06-18 2010-04-27 Biolipox Ab Indoles useful in the treatment of inflammation
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7741326B2 (en) 2006-11-09 2010-06-22 Roche Palo Alto Llc Indole and benzofuran 2-carboxamide derivatives and uses thereof
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
US8097623B2 (en) 2005-01-19 2012-01-17 Biolipox Ab Indoles useful in the treatment of inflammation
EP2431029A2 (en) 2002-06-07 2012-03-21 Kieran Francis Scott Method of inhibiting prostate cancer cell proliferation
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8394969B2 (en) 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8440691B2 (en) 2004-11-24 2013-05-14 Abbvie Inc. Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
US8563746B2 (en) 2008-10-29 2013-10-22 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9000025B2 (en) 2010-08-20 2015-04-07 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9018210B2 (en) 2011-12-28 2015-04-28 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
CN104876849A (en) * 2015-01-15 2015-09-02 昆明理工大学 Indole derivative and applications thereof
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
US9388161B2 (en) 2013-11-18 2016-07-12 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as BET bromodomain inhibitors
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9447071B2 (en) 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9573958B2 (en) 2012-08-31 2017-02-21 Principia Biopharma, Inc. Benzimidazole derivatives as ITK inhibitors
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
US9957250B2 (en) 2013-03-15 2018-05-01 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9981939B2 (en) 2013-03-15 2018-05-29 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10004725B2 (en) 2015-03-30 2018-06-26 Global Blood Therapeutics, Inc. Methods of treatment
US10077249B2 (en) 2016-05-12 2018-09-18 Global Blood Therapeutics, Inc. Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10377769B2 (en) 2013-11-18 2019-08-13 Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10493035B2 (en) 2016-10-12 2019-12-03 Global Blood Therapeutics, Inc. Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11236109B2 (en) 2013-03-15 2022-02-01 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11426407B2 (en) 2014-10-06 2022-08-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US11453655B2 (en) 2016-12-09 2022-09-27 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2023151291A1 (en) * 2022-02-11 2023-08-17 北京青颜博识健康管理有限公司 1,3-disubstituted indole derivative as hyaluronidase inhibitor and use thereof in cosmetic product

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
JP5001650B2 (en) * 2003-07-11 2012-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzimidazole carboxamide
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
WO2005113499A1 (en) * 2004-05-20 2005-12-01 Sankyo Company, Limited Indole compounds
WO2006109633A1 (en) * 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited Substituted indole compound
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
CN103338767B (en) * 2010-08-04 2018-06-22 弗吉尼亚大学专利基金会 Treat the composition and method of diseases associated with inflammation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0620215A1 (en) * 1993-04-16 1994-10-19 Eli Lilly And Company 1H-indole-3-acetamide derivatives as sPLA2 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0620215A1 (en) * 1993-04-16 1994-10-19 Eli Lilly And Company 1H-indole-3-acetamide derivatives as sPLA2 inhibitors

Cited By (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569539B2 (en) 1996-10-30 2003-05-27 Tetra Level Holdings & Finance S.A. Gas barrier packaging laminate method for production thereof and packaging containers
EP0995742A1 (en) * 1997-06-27 2000-04-26 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
EP0995742A4 (en) * 1997-06-27 2004-08-25 Fujisawa Pharmaceutical Co Sulfonamide compounds and medicinal use thereof
US6911469B2 (en) 1997-06-27 2005-06-28 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and pharmaceutical use thereof
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
WO1999043651A2 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO1999043672A1 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase a2
WO1999043654A3 (en) * 1998-02-25 1999-10-28 Genetics Inst Inhibitors of phospholipase enzymes
WO1999043654A2 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO1999043651A3 (en) * 1998-02-25 1999-12-16 Genetics Inst Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
USRE38624E1 (en) * 1998-04-28 2004-10-12 Elbion Ag Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation
US6251923B1 (en) 1998-04-28 2001-06-26 Arzneimittelwerk Dresden Gmbh Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation
DE19818964A1 (en) * 1998-04-28 1999-11-04 Dresden Arzneimittel New hydroxy-indole derivatives useful in treatment of degenerative joint disease, viral and parasitic infections, bronchial, dermatological, neurodegenerative and prostate disorders, etc.
US7268145B2 (en) 1998-07-15 2007-09-11 Teijin Pharma Limited Thiobenzimidazole derivatives
DE19917504A1 (en) * 1999-04-17 2000-10-19 Dresden Arzneimittel New hydroxy-indole derivatives, useful in treatment of degenerative joint disease, viral and parasitic infections, bronchial, dermatological, neurodegenerative and prostate disorders, etc.
US6924301B1 (en) 1999-10-22 2005-08-02 Shionogi & Co., Ltd. Composition for treating or preventing arrhythmia
US6492550B2 (en) 2000-02-18 2002-12-10 Bristol-Myers Squibb Company Alpha-substituted thio, -oxo trifluoromethylketones as phospholipase inhibitors
US6414179B1 (en) 2000-02-18 2002-07-02 Bristol-Myers Squibb Company Alpha-and beta-substituted trifluoromethyl ketones as phospholipase inhibitors
US6924391B2 (en) 2000-05-11 2005-08-02 Bristol-Myers Squibb Company Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors
WO2002000620A1 (en) * 2000-06-27 2002-01-03 Smithkline Beecham Corporation Fatty acid synthase inhibitors
US6670388B1 (en) 2000-06-27 2003-12-30 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
WO2002005796A3 (en) * 2000-07-14 2002-09-06 Lilly Co Eli Use of a spla2 inhibitor for the treatment of sepsis
US6525083B2 (en) 2000-07-25 2003-02-25 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6686384B2 (en) 2000-12-05 2004-02-03 Aventis Pharma Deutschland Gmbh Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them
US6958357B2 (en) 2000-12-05 2005-10-25 Aventis Pharma Deutschland Gmbh Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them
CN100471838C (en) * 2000-12-28 2009-03-25 第一制药株式会社 VLA-4 inhibitors
US7157487B2 (en) 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
WO2002053534A1 (en) 2000-12-28 2002-07-11 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
US6939886B2 (en) 2001-06-20 2005-09-06 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1)
US6800654B2 (en) 2001-06-20 2004-10-05 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7629377B2 (en) 2001-06-20 2009-12-08 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7368471B2 (en) 2001-06-20 2008-05-06 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7351730B2 (en) 2001-06-20 2008-04-01 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7410994B2 (en) 2001-09-27 2008-08-12 Roche Palo Alto Llc Indole derivatives as anti-inflammatory agents
US6872744B2 (en) 2001-09-27 2005-03-29 Syntex (U.S.A.) Llc Indole derivatives as anti-inflammatory agents
US7074939B2 (en) 2001-09-27 2006-07-11 Roche Palo Alto Llc Indole derivatives as anti-inflammatory agents
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US7906548B2 (en) 2001-12-03 2011-03-15 Wyeth Llc Methods for the use of inhibitors of cytosolic phospholipase A2
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US6933316B2 (en) 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
US7632955B2 (en) 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
EP2431029A2 (en) 2002-06-07 2012-03-21 Kieran Francis Scott Method of inhibiting prostate cancer cell proliferation
US7022714B2 (en) 2002-07-31 2006-04-04 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
US7345085B2 (en) 2002-08-29 2008-03-18 Merck & Co., Inc. Indoles having anti-diabetic activity
US7186746B2 (en) 2002-08-29 2007-03-06 Merck & Co., Inc. Indoles having anti-diabetic activity
US7674818B2 (en) 2002-12-10 2010-03-09 Wyeth Llc Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7566791B2 (en) 2002-12-10 2009-07-28 Wyeth Substituted 3-carbonyl-1h-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7259182B2 (en) 2002-12-10 2007-08-21 Wyeth Aryl, aryloxy, and aklyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7160918B2 (en) 2002-12-10 2007-01-09 Hassan Mahmoud Elokdah Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor (PAI-1)
US7078429B2 (en) 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7101903B2 (en) 2002-12-10 2006-09-05 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1)
US7459478B2 (en) 2002-12-10 2008-12-02 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
EP1633716A4 (en) * 2003-04-16 2008-03-26 Bristol Myers Squibb Co Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors
EP1633716A2 (en) * 2003-04-16 2006-03-15 Bristol-Myers Squibb Company Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors
US7691894B2 (en) 2003-07-24 2010-04-06 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US7893279B2 (en) 2003-07-24 2011-02-22 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7803835B2 (en) 2003-09-25 2010-09-28 Wyeth Llc Substituted acetic acid derivatives
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US8053450B2 (en) 2004-01-21 2011-11-08 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors with pyridine ring and heterocyclic components
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
EP1750699A4 (en) * 2004-05-03 2008-01-09 Ilypsa Inc Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds
EP1750730A4 (en) * 2004-05-03 2008-01-09 Ilypsa Inc Treatment of hypercholesterolemia, hypertriglyceridemia and cardiovascular-related conditions using phosphalipase-a2 inhibitors
EP1750730A2 (en) * 2004-05-03 2007-02-14 Ilypsa, Inc. Treatment of hypercholesterolemia, hypertriglyceridemia and cardiovascular-related conditions using phosphalipase-a2 inhibitors
EP1750699A2 (en) * 2004-05-03 2007-02-14 Ilypsa, Inc. Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds
US7705023B2 (en) 2004-06-18 2010-04-27 Biolipox Ab Indoles useful in the treatment of inflammation
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
US8440691B2 (en) 2004-11-24 2013-05-14 Abbvie Inc. Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
US8097623B2 (en) 2005-01-19 2012-01-17 Biolipox Ab Indoles useful in the treatment of inflammation
US7323483B2 (en) 2005-01-27 2008-01-29 Wyeth Processes and compounds for the preparation of substituted naphthylindole derivatives
US7557135B2 (en) 2005-05-27 2009-07-07 Wyeth Inhibitors of cytosolic phospholipase A2
US8283373B2 (en) 2005-05-27 2012-10-09 Pfizer Inc. Inhibitors of cytosolic phospholipase A2
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
US7741326B2 (en) 2006-11-09 2010-06-22 Roche Palo Alto Llc Indole and benzofuran 2-carboxamide derivatives and uses thereof
US8394969B2 (en) 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8563746B2 (en) 2008-10-29 2013-10-22 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9000025B2 (en) 2010-08-20 2015-04-07 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
US9849109B2 (en) 2010-08-20 2017-12-26 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
US9018210B2 (en) 2011-12-28 2015-04-28 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US10806733B2 (en) 2011-12-28 2020-10-20 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US10377741B2 (en) 2011-12-28 2019-08-13 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US10034879B2 (en) 2011-12-28 2018-07-31 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US10822326B2 (en) 2011-12-28 2020-11-03 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9573958B2 (en) 2012-08-31 2017-02-21 Principia Biopharma, Inc. Benzimidazole derivatives as ITK inhibitors
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10858317B2 (en) 2013-03-15 2020-12-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11236109B2 (en) 2013-03-15 2022-02-01 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9776960B2 (en) 2013-03-15 2017-10-03 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11530191B2 (en) 2013-03-15 2022-12-20 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9957250B2 (en) 2013-03-15 2018-05-01 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9981939B2 (en) 2013-03-15 2018-05-29 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10435393B2 (en) 2013-03-15 2019-10-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10017491B2 (en) 2013-03-15 2018-07-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10100040B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10829470B2 (en) 2013-03-15 2020-11-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10315991B2 (en) 2013-03-15 2019-06-11 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
US9388161B2 (en) 2013-11-18 2016-07-12 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as BET bromodomain inhibitors
US10336722B2 (en) 2013-11-18 2019-07-02 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as BET bromodomain inhibitors
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11111229B2 (en) 2013-11-18 2021-09-07 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as BET bromodomain inhibitors
US11084831B1 (en) 2013-11-18 2021-08-10 Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors
US10611750B2 (en) 2013-11-18 2020-04-07 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as bet bromodomain inhibitors
US10703764B2 (en) 2013-11-18 2020-07-07 Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors
US10377769B2 (en) 2013-11-18 2019-08-13 Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors
US10722502B2 (en) 2014-02-07 2020-07-28 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10137118B2 (en) 2014-02-07 2018-11-27 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11452720B2 (en) 2014-02-07 2022-09-27 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9447071B2 (en) 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11426407B2 (en) 2014-10-06 2022-08-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN104876849A (en) * 2015-01-15 2015-09-02 昆明理工大学 Indole derivative and applications thereof
CN104876849B (en) * 2015-01-15 2017-05-10 昆明理工大学 Indole derivative and applications thereof
US10004725B2 (en) 2015-03-30 2018-06-26 Global Blood Therapeutics, Inc. Methods of treatment
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11944612B2 (en) 2015-12-04 2024-04-02 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10077249B2 (en) 2016-05-12 2018-09-18 Global Blood Therapeutics, Inc. Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
US10577345B2 (en) 2016-05-12 2020-03-03 Global Blood Therapeutics, Inc. Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
US10493035B2 (en) 2016-10-12 2019-12-03 Global Blood Therapeutics, Inc. Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11453655B2 (en) 2016-12-09 2022-09-27 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
WO2023151291A1 (en) * 2022-02-11 2023-08-17 北京青颜博识健康管理有限公司 1,3-disubstituted indole derivative as hyaluronidase inhibitor and use thereof in cosmetic product

Also Published As

Publication number Publication date
JP2000516958A (en) 2000-12-19
EP0922028A1 (en) 1999-06-16
AU4088297A (en) 1998-03-19
CA2264020A1 (en) 1998-03-05
AU717430B2 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
WO1998008818A1 (en) Inhibitors of phospholipase enzymes
WO1999043672A1 (en) Inhibitors of phospholipase a2
US6630496B1 (en) Inhibitors of phospholipase enzymes
EP1307457B1 (en) Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
EP1720872B1 (en) Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors
BE1006343A5 (en) Derivatives indole.
EP1708994B1 (en) Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics
EP0302788B1 (en) 2-[Methyl(4-piperidinyl)]-1,2,3,4-tetrahydro-9H-pyrido[3,4-b] indole derivatives, their preparation and therapeutical use
JPS63246372A (en) 3-hetero substituted-n-benzyl-indole
FR2722190A1 (en) 1-BENZYL-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2522324A1 (en) PYRROLE ACETAMIDES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITION CONTAINING SAME
EP0008249B1 (en) Fluorene and fluoranthene derivatives, process for their preparation and their therapeutic application
EP1189903B1 (en) Novel benzo[f]naphthyridine, preparation and compositions containing them
JP2661841B2 (en) Indoline derivatives
SK86593A3 (en) Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives
US5151437A (en) Benzofurancarboxamides having basic substituents and therapeutic agents containing the same
BE1005612A5 (en) Derivative dichloroaniline.
MXPA99001864A (en) Inhibitors of phospholipase enzymes
EP0359627A1 (en) 2,3-Dihydro-3-arylalkylaminoalkyl-4H-1,3-benzoxazin-4-one derivatives, their preparation and their use as therapeutic agents
CN114436945B (en) Benzenesulfonamide compound, preparation method and application
EP0820434B1 (en) Phenoxyethylamine derivatives having high affinity for the 5-ht 1a receptor, preparation thereof, use thereof as drugs, and pharmaceutical compositions containing said derivatives
SK86693A3 (en) New isobutylsubstituted amids metansulfonyl-quinolylmeto- xyphenylcycloalkylacetic acid
CZ20003117A3 (en) Phospholipase inhibitors
MXPA00008294A (en) Inhibitors of phospholipase a2
IE911909A1 (en) Antihypercholesterolemic bis-trifluoromethyl-substituted¹Imidazolines and derivatives thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2264020

Country of ref document: CA

Ref country code: CA

Ref document number: 2264020

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/001864

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 511798

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997938589

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997938589

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997938589

Country of ref document: EP